Bispecific antibody fusion molecules targeting GPRC5d and CD3 and methods of use thereof

Abstract

The present disclosure provides bispecific and multispecific antibodies or antigen binding fragments thereof that specifically bind to CD 3 and GPRC5D. The antibodies are optionally fused with a CD58 peptide or portions thereof. Described herein are methods of making and using the bispecific antibodies for treatment of cancers that express GPRC5D. The present disclosure also relates to methods and kits for detecting a predisposition to, determining the risk of, and guiding therapy for GPRC5D related disorders.

Description

Attorney Docket No. E0701.70010WO00 BISPECIFIC ANTIBODY FUSION MOLECULES TARGETING GPRC5D AND CD3 AND METHODS OF USE THEREOF RELATED APPLICATIONS

[0001] This application claims benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No.63 / 659,205, filed June 12, 2024, entitled “Bispecific Antibody Fusion Molecules Targeting GPRC5D and CD3 and Methods of Use Thereof”, the entire contents of which are incorporated herein by reference. REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The contents of the electronic sequence listing (E070170010WO00-SEQ-LJG.xml; Size: 335,411 bytes; and Date of Creation: June 12, 2025) are herein incorporated by reference in its entirety. FIELD

[0003] This disclosure relates to the pharmaceutical compositions of bispecific antibodies that bind to GPRC5D or BCMA and CD3; multispecific antibodies that bind GPRC5D and BCMA, and CD3; as well as multispecific antibodies that bind to GPRD5D and / or BCMA, CD3 and CD2, and their use for treating GPRC5D and BCMA-expressing cancers. This disclosure also relates to a method and kits for detecting a predisposition to, determining the risk of, and guiding therapy for cancers. BACKGROUND

[0004] G-protein coupled receptor, class C, group 5, member D (GPRC5D)is a unique, atypical, class C GPCR first identified in 2001 (Bräuner-Osborne et al. Biochim Biophys Acta.1518(3):237-248, 2001). GPRC5D and other group 5 GPCRs have unusually short amino-terminal domains for class C receptors and are predicted to be conformationally similar to class A receptors. The functional consequence of GPRC5D activation has not been described, and GPRC5D is an orphan receptor with an unknown ligand. The GPRC5D gene has three exons and is located on chromosome 12p13.3 in humans. The GPRC5D protein is highly conserved among various species and shares 92% identity with cynomolgus monkey GPRC5D. This disclosure, however, presents a unique approach by 1 304743675Attorney Docket No. E0701.70010WO00 using bispecific antibodies that bind GPRC5D and CD3, offering a unique method for cancer therapy.

[0005] GPRC5D mRNA is predominantly expressed in malignant plasma cells from multiple myeloma patients (Atamaniuk J A et al. Eur J Clin Invest 42(9) 953-960; 2012; Frigyesi- blood and Cohen, et al. Hematology 18(6): 348-35; 2013). GPRC5D expression is variable among patients, and correlates well with plasma cell burden and genetic aberrations such as Rb-1 deletion (Atamaniuk J A et al. Eur J Clin Invest 42(9) 953-960; 2012).

[0006] The use of anti-GPRC5D antibodies for the treatment of multiple myeloma is mentioned in WO2016090329, WO2018017786, WO2018147245, and WO2019154890. While >60% of patients experience a positive response to these therapies, there is an opportunity for improved clinical response, and therefore, additional GPRC5D targeted therapy options are needed for the treatment of unresponsive or refractory patients (Rodriguez-Otero et al. Blood Cancer J. (2024) 14, 24).

[0007] B-cell maturation antigen, also known as BCMA, CD269, TNFRSF17 (UniProt Q02223), is a member of the tumor necrosis receptor superfamily that is preferentially expressed in differentiated plasma cells [Laabi et al. (1992) EMBO J 11(11):3897-3904; Madry et al. (1998) Int Immunol 10(11):1693-1702]. BCMA is a non-glycosylated type I transmembrane protein involved in B cell maturation, growth, and survival. BCMA is a receptor for two ligands of the TNF superfamily: APRIL (a proliferation-inducing ligand, CD256, TNFSF13), the high-affinity ligand to BCMA, and the B cell activation factor BAFF (THANK, BlyS, B lymphocyte stimulator, TALL-1 and zTNF4), the low-affinity ligand to BCMA. APRIL and BAFF show structural similarity and overlapping yet distinct receptor binding specificity. The negative regulator TACI also binds to both BAFF and APRIL. The coordinate binding of APRIL and BAFF to BCMA and / or TACI activates transcription factor NF-xB and increases the expression of pro-survival Bcl-2 family members (e.g., Bcl-2, Bcl- xL, Bcl-w, Mcl-1, A1) and down regulates expression of pro-apoptotic factors (e.g., Bid, Bad, Bik, Bim, etc.), thus inhibiting apoptosis and promoting survival. This combined action promotes B cell differentiation, proliferation, survival, and antibody production (as reviewed in Rickert R C et al., Immunol Rev (2011) 244 (1): 115-133). In line with this finding, BCMA also supports the growth and survival of malignant human B cells, including multiple myeloma (MM) cells. Novak et al. found that MM cell lines and freshly isolated MM cells express BCMA and TACI protein on their cell surfaces and have variable expression of BAFF-R protein on their cell surface (Novak et al., (2004) Blood 103(2):689-694). 2 304743675Attorney Docket No. E0701.70010WO00

[0008] The use of anti-BCMA antibodies for the treatment of lymphomas and multiple myeloma is mentioned in WO2002066516 and WO2010104949. Antibodies against BCMA are described, e.g., in Gras M-P. et al. Int Immunol.7 (1995) 1093-1106, WO200124811, and WO200124812. Nevertheless, despite the fact that BCMA, BAFF-R, and TACI, i.e., B cell receptors belonging to the TNF receptor superfamily, and their ligands BAFF and APRIL are subject to therapies in fighting against cancer, further options for the treatment of such medical conditions are needed.

[0009] There is a continued need to develop agents that target GPRC5D that are efficacious and safe for human use. There is a need in the art for agents that target GPRC5D for the diagnosis and treatment of GPRC5D associated conditions, such as cancers. Further, there exists a need for methods and kits to identify whether a subject with a GPRC5D expressing cancer will be responsive to such antibody-based therapies. Provided herein are methods and compositions addressing this need. SUMMARY

[0010] The disclosure provides an antibody comprising a first antigen binding region that binds to GPRC5D, a second antigen binding region that binds to GPRC5D, and a third antigen binding region that binds to CD3, wherein the first antigen binding region that binds to GPRC5D comprises three heavy chain complementarity determining regions (VH1_CDR1, VH1_CDR2, VH1_CDR3) and three light chain complementarity determining regions (VL1_CDR1, VL1_CDR2, VL1_CDR3), wherein a) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 72; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 82; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 83; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 89; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 98; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 100; b) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 86; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; c) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH1_CDR3 comprises the amino 3 304743675Attorney Docket No. E0701.70010WO00 acid sequence of SEQ ID NO: 85; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; or d) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 77; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 79; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 88; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 93; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 94; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 103; wherein the second antigen binding region that binds to GPRC5D comprises three heavy chain complementarity determining regions (VH2_CDR1, VH2_CDR2, VH2_CDR3) and three light chain complementarity determining regions (VL2_CDR1, VL2_CDR2, VL2_CDR3), wherein I) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 72; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 82; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 83; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 89; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 98; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 100; II) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 72; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 97; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 83; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 89; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 98; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 100; III) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 86; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; or IV) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 77; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 79; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 88; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 93; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 94; andVL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 103; and wherein the third antigen binding region that binds to CD3 comprises three heavy chain complementarity determining regions (VH3_CDR1, VH3_CDR2, VH3_CDR3) and 4 304743675Attorney Docket No. E0701.70010WO00 three light chain complementarity determining regions (VL3_CDR1, VL3_CDR2, VL3_CDR3), wherein i) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 73; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; andVL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; ii) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 74; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 95; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; iii) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 76; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 92; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 104; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 102; iv) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 74; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; or v) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 73; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 95; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 87.

[0011] In some aspects, the first antigen binding region that binds to GPRC5D comprises a first variable heavy chain region (VH1) and a first variable light chain region (VL1), wherein: a) VH1 comprises the amino acid sequence of SEQ ID NO: 117; and VL1 comprises the amino acid sequence of SEQ ID NO: 131; 304743675Attorney Docket No. E0701.70010WO00 b) VH1 comprises the amino acid sequence of SEQ ID NO: 120; and VL1 comprises the amino acid sequence of SEQ ID NO: 135; c) VH1 comprises the amino acid sequence of SEQ ID NO: 122; and VL1 comprises the amino acid sequence of SEQ ID NO: 137; or d) VH1 comprises the amino acid sequence of SEQ ID NO: 123; and VL1 comprises the amino acid sequence of SEQ ID NO: 138; wherein the second antigen binding region that binds to GPRC5D comprises a second variable heavy chain region (VH2) and a second variable light chain region (VL2), wherein: I) VH1 comprises the amino acid sequence of SEQ ID NO: 117; and VL1 comprises the amino acid sequence of SEQ ID NO: 131; II) VH1 comprises the amino acid sequence of SEQ ID NO: 120; and VL1 comprises the amino acid sequence of SEQ ID NO: 135; III) VH1 comprises the amino acid sequence of SEQ ID NO: 122; and VL1 comprises the amino acid sequence of SEQ ID NO: 137; or IV) VH1 comprises the amino acid sequence of SEQ ID NO: 123; and VL1 comprises the amino acid sequence of SEQ ID NO: 138; and wherein the third antigen binding region that binds to CD3 comprises a third variable heavy chain region (VH3) and a third variable light chain region (VL3), wherein: i) VH3 comprises the amino acid sequence of SEQ ID NO: 118; and VL3 comprises the amino acid sequence of SEQ ID NO: 132; ii) VH3 comprises the amino acid sequence of SEQ ID NO: 119; and VL3 comprises the amino acid sequence of SEQ ID NO: 133; iii) VH3 comprises the amino acid sequence of SEQ ID NO: 119; and VL3 comprises the amino acid sequence of SEQ ID NO: 132; or iv) VH3 comprises the amino acid sequence of SEQ ID NO: 121; and VL3 comprises the amino acid sequence of SEQ ID NO: 136.

[0012] In some aspects, the antibody comprises a first heavy chain polypeptide (H1) and a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), and a third light chain polypeptide (L3), wherein

[0013] a) the first heavy chain polypeptide (H1) comprises the second variable heavy chain region (VH2);

[0014] b) the second heavy chain polypeptide (H2) comprises the third variable heavy chain region (VH3); 304743675Attorney Docket No. E0701.70010WO00

[0015] c) the first variable heavy chain region (VH1) is located on either the first heavy chain polypeptide (H1) or the second heavy chain polypeptide (H2),

[0016] d) the first light chain polypeptide (L1) comprises the first variable light chain region (VL1),

[0017] e) the second light chain polypeptide (L2) comprises the second variable light chain region (VL2), and

[0018] f) the third light chain polypeptide (L3) comprises the third variable light chain region (VL3).

[0019] In some aspects, a polypeptide is fused to the N-terminus or the C-terminus of the first heavy chain polypeptide (H1), the second heavy chain polypeptide (H2), or the third light chain polypeptide (L3).

[0020] In some aspects, the polypeptide is fused via a linker peptide.

[0021] In some aspects, the polypeptide comprises CD58 or a fragment thereof.

[0022] In some aspects, the CD58 comprises the amino acid sequence of SEQ ID NO: 144.

[0023] In some aspects, the antibody of any embodiment of the disclosure, wherein i) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 117; the VH3 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; the VL2 comprises the amino acid sequence of SEQ ID NO: 131; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; ii) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 117; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; the VL2 comprises the amino acid sequence of SEQ ID NO: 131; and the VL3 comprises the amino acid sequence of SEQ ID NO: 133; iii) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 117; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; the VL2 comprises the amino acid sequence of SEQ ID NO: 131; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; iv) the VH1 comprises the amino acid sequence of SEQ ID NO: 120; the VH2 comprises the amino acid sequence of SEQ ID NO: 120; the VH3 comprises the amino acid sequence of SEQ ID NO: 121; the VL1 comprises the amino acid sequence of SEQ ID NO: 7 304743675Attorney Docket No. E0701.70010WO00 135; the VL2 comprises the amino acid sequence of SEQ ID NO: 135; and the VL3 comprises the amino acid sequence of SEQ ID NO: 136; v) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 122; the VH3 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; the VL2 comprises the amino acid sequence of SEQ ID NO: 137; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; vi) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 122; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; the VL2 comprises the amino acid sequence of SEQ ID NO: 137; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; vii) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 123; the VH3 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; the VL2 comprises the amino acid sequence of SEQ ID NO: 138; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; viii) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 123; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; the VL2 comprises the amino acid sequence of SEQ ID NO: 138; and the VL3 comprises the amino acid sequence of SEQ ID NO: 133; or ix) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 123; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; the VL2 comprises the amino acid sequence of SEQ ID NO: 138; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132.

[0024] In some aspects, i) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 8; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; 304743675Attorney Docket No. E0701.70010WO00 ii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 9; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; iii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 9; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59;

[0025] iv) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 10; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61;

[0026] v) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; vi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; vii) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 10; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; viii) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; ix) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; 304743675Attorney Docket No. E0701.70010WO00 x) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xi) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xii) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xiii) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xiv) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; xv) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xvi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 16; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xvii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 17; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; 304743675Attorney Docket No. E0701.70010WO00 xviii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 17; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xix) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 10; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; xx) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 64; xxi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; xxii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 18; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 19; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 19; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxv) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 20; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; 304743675Attorney Docket No. E0701.70010WO00 xxvi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 21; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; xxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 21; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 22; the H2 comprises the amino acid sequence of SEQ ID NO: 23; the L1 comprises the amino acid sequence of SEQ ID NO: 65; the L2 comprises the amino acid sequence of SEQ ID NO: 65; and the L3 comprises the amino acid sequence of SEQ ID NO: 66; xxix) the H1 comprises the amino acid sequence of SEQ ID NO: 22; the H2 comprises the amino acid sequence of SEQ ID NO: 24; the L1 comprises the amino acid sequence of SEQ ID NO: 65; the L2 comprises the amino acid sequence of SEQ ID NO: 65; and the L3 comprises the amino acid sequence of SEQ ID NO: 66; xxx) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 27; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxxi) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 28; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xxxii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 28; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 29; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; 304743675Attorney Docket No. E0701.70010WO00 xxxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; xxxv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xxxvi) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 29; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xxxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxxix) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xl) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xli) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; 304743675Attorney Docket No. E0701.70010WO00 xlii) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xliii) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; xliv) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xlv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 33; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xlvi) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 34; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xlvii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 34; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xlviii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 29; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; xlix) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 64; 304743675Attorney Docket No. E0701.70010WO00 l) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; li) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 35; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 36; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; liii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 36; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; liv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 37; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 38; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; lvi) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 38; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lvii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 43; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; 304743675Attorney Docket No. E0701.70010WO00 lviii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 44; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lix) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 44; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lx) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 45; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lxi) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; lxii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 45; L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lxv) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; 304743675Attorney Docket No. E0701.70010WO00 lxvi) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lxix) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lxx) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; lxxi) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lxxii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 147; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 148; L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; 304743675Attorney Docket No. E0701.70010WO00 lxxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 148; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxxv) the H1 comprises the amino acid sequence of SEQ ID NO: 42;the H2 comprises the amino acid sequence of SEQ ID NO: 45; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 64; lxxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; lxxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 51; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxxix) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 149; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lxxx) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 149; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxxxi) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 150; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lxxxii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 151; the L1 comprises the amino acid sequence of 304743675Attorney Docket No. E0701.70010WO00 SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; or lxxxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 151; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61.

[0027] The disclosure provides a polynucleotide comprising a nucleic acid sequence encoding the antibody of any embodiment of the disclosure.

[0028] The disclosure provides a vector comprising the polynucleotide of any embodiment of the disclosure.

[0029] The disclosure provides a pharmaceutical composition comprising the antibody of any embodiment of the disclosure, the polynucleotide of any embodiment of the disclosure, or the vector of any embodiment of the disclosure, and a pharmaceutically acceptable carrier.

[0030] The disclosure provides a bispecific antibody comprising a first antigen binding region that binds to GPRC5D, and a second antigen binding region that binds to CD3, wherein the first antigen binding region that binds to GPRC5D comprises three heavy chain complementarity determining regions (VH1_CDR1, VH1_CDR2, VH1_CDR3) and three light chain complementarity determining regions (VL1_CDR1, VL1_CDR2, VL1_CDR3), wherein a) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 72; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 82; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 83; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 89; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 98; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 100; b) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 86; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; c) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; 19 304743675Attorney Docket No. E0701.70010WO00 VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 85; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; or d) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 77; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 79; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 88; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 93; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 94; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 103; wherein the second antigen binding region that binds to CD3 comprises three heavy chain complementarity determining regions (VH2_CDR1, VH2_CDR2, VH2_CDR3) and three light chain complementarity determining regions (VL2_CDR1, VL2_CDR2, VL2_CDR3), wherein i) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 74; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 104; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; ii) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 73; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; or iii) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 74; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 95; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; or 20 304743675Attorney Docket No. E0701.70010WO00 iv) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 92; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 104; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 102; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 76; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 87.

[0031] In some aspects, the first antigen binding region that binds to GPRC5D comprises a first variable heavy chain region (VH1) and a first variable light chain region (VL1), wherein: a) VH1 comprises the amino acid sequence of SEQ ID NO: 126; and VL1 comprises the amino acid sequence of SEQ ID NO: 143; b) VH1 comprises the amino acid sequence of SEQ ID NO: 117; and VL1 comprises the amino acid sequence of SEQ ID NO: 131; c) VH1 comprises the amino acid sequence of SEQ ID NO: 122; and VL1 comprises the amino acid sequence of SEQ ID NO: 137; or d) VH1 comprises the amino acid sequence of SEQ ID NO: 123; and VL1 comprises the amino acid sequence of SEQ ID NO: 138; wherein the second antigen binding region that binds to CD3 comprises a second variable heavy chain region (VH2) and a second variable light chain region (VL2), wherein: i) VH2 comprises the amino acid sequence of SEQ ID NO: 125; and VL2 comprises the amino acid sequence of SEQ ID NO: 142; ii) VH2 comprises the amino acid sequence of SEQ ID NO: 127; and VL2 comprises the amino acid sequence of SEQ ID NO: 142; iii) VH2 comprises the amino acid sequence of SEQ ID NO: 118; and VL2 comprises the amino acid sequence of SEQ ID NO: 132; iv) VH2 comprises the amino acid sequence of SEQ ID NO: 119; and VL2 comprises the amino acid sequence of SEQ ID NO: 133; v) VH2 comprises the amino acid sequence of SEQ ID NO: 119; and VL2 comprises the amino acid sequence of SEQ ID NO: 132; or vi) VH2 comprises the amino acid sequence of SEQ ID NO: 128; and VL2 comprises the amino acid sequence of SEQ ID NO: 141. 304743675Attorney Docket No. E0701.70010WO00

[0032] In some aspects, the bispecific antibody comprises a first heavy chain polypeptide (H1) and a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2) wherein, a) the first heavy chain polypeptide (H1) comprises the first variable heavy chain region (VH1); b) the second heavy chain polypeptide (H2) comprises the second variable heavy chain region (VH2); c) the first light chain polypeptide (L1) comprises the first variable light chain region (VL1); and d) the second light chain polypeptide (L2) comprises the second variable light chain region (VL2). In some aspects, a polypeptide is fused to the N-terminus or the C-terminus of the first heavy chain polypeptide (H1), the second heavy chain polypeptide (H2), or the third light chain polypeptide (L3).

[0033] In some aspects, the polypeptide is fused via a linker peptide.

[0034] In some aspects, the polypeptide comprises CD58 or a fragment thereof.

[0035] In some aspects, the CD58 comprises the amino acid sequence of SEQ ID NO: 144.

[0036] In some aspects,

[0037] i) the VH1 comprises the amino acid sequence of SEQ ID NO: 126; the VH2 comprises the amino acid sequence of SEQ ID NO: 125; the VL1 comprises the amino acid sequence of SEQ ID NO: 143; and the VL2 comprises the amino acid sequence of SEQ ID NO: 142; ii) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 127; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; and the VL2 comprises the amino acid sequence of SEQ ID NO: 142; iii) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132; iv) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; and 304743675Attorney Docket No. E0701.70010WO00 the VL2 comprises the amino acid sequence of SEQ ID NO: 133; v) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132; vi) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 128; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; and the VL2 comprises the amino acid sequence of SEQ ID NO: 141; vii) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132; viii) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; and the VL2 comprises the amino acid sequence of SEQ ID NO: 133; ix) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132; x) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132; xi) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; and the VL2 comprises the amino acid sequence of SEQ ID NO: 133; or xii) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132. 304743675Attorney Docket No. E0701.70010WO00

[0038] In some aspects,

[0039] i) the H1 comprises the amino acid sequence of SEQ ID NO: 1; the H2 comprises the amino acid sequence of SEQ ID NO: 2; the L1 comprises the amino acid sequence of SEQ ID NO: 55; and the L2 comprises the amino acid sequence of SEQ ID NO: 56; ii) the H1 comprises the amino acid sequence of SEQ ID NO: 1; the H2 comprises the amino acid sequence of SEQ ID NO: 3; the L1 comprises the amino acid sequence of SEQ ID NO: 55; and the L2 comprises the amino acid sequence of SEQ ID NO: 56; iii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 5; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 58; iv) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; v) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; vi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; vii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; viii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 62; 304743675Attorney Docket No. E0701.70010WO00 xi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; x) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xi) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; xii) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xiii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 26; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 68; xiv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 65; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; xvi) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xvii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; 304743675Attorney Docket No. E0701.70010WO00 the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; xviii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 62; xix) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; xx) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xxi) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; xxii) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; xxv) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 7; 304743675Attorney Docket No. E0701.70010WO00 the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xxvi) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; xxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 62; xxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; xxix) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xxx) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; or xxxi) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 59.

[0040] The disclosure provides a polynucleotide comprising a nucleic acid sequence encoding the bispecific antibody of any embodiment of the disclosure.

[0041] The disclosure provides a vector comprising the polynucleotide of any embodiment of the disclosure.

[0042] The disclosure provides a pharmaceutical composition comprising the bispecific antibody of any embodiment of the disclosure, the polynucleotide of any embodiment of the 27 304743675Attorney Docket No. E0701.70010WO00 disclosure, or the vector any embodiment of the disclosure, and a pharmaceutically acceptable carrier.

[0043] The disclosure provides a trispecific antibody comprising a first antigen binding region that binds to GPRC5D, a second antigen binding region that binds to BCMA, and a third antigen binding region that binds to CD3, wherein the first antigen binding region that binds to GPRC5D comprises three heavy chain complementarity determining regions (VH1_CDR1, VH1_CDR2, VH1_CDR3) and three light chain complementarity determining regions (VL1_CDR1, VL1_CDR2, VL1_CDR3), wherein a) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 77; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 79; and VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 88; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 93; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 94; VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 103; wherein the second antigen binding region that binds to BCMA comprises three heavy chain complementarity determining regions (VH2_CDR1, VH2_CDR2, VH2_CDR3) and three light chain complementarity determining regions (VL2_CDR1, VL2_CDR2, VL2_CDR3), wherein I) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 111; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 112; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 113; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 105; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 106; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 107; and wherein the third antigen binding region that binds to CD3 comprises three heavy chain complementarity determining regions (VH3_CDR1, VH3_CDR2, VH3_CDR3) and three light chain complementarity determining regions (VL3_CDR1, VH3_CDR2, VH3_CDR3), wherein i) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 108; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 109; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 110; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 114; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 115; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 116.

[0044] In some aspects, the first antigen binding region that binds to GPRC5D comprises a first variable heavy chain region (VH1) and a first variable light chain region (VL1), wherein: 304743675Attorney Docket No. E0701.70010WO00 a) VH1 comprises the amino acid sequence of SEQ ID NO: 139; and VL1 comprises the amino acid sequence of SEQ ID NO: 129; wherein the second antigen binding region that binds to BCMA comprises a second variable heavy chain region (VH2) and a second variable light chain region (VL2), wherein: I) VH1 comprises the amino acid sequence of SEQ ID NO: 145; and VL1 comprises the amino acid sequence of SEQ ID NO: 146; and wherein the third antigen binding region that binds to CD3 comprises a third variable heavy chain region (VH3) and a third variable light chain region (VL3), wherein: i) VH3 comprises the amino acid sequence of SEQ ID NO: 130; and VL3 comprises the amino acid sequence of SEQ ID NO: 140.

[0045] In some aspects, the trispecific antibody comprises a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a third heavy chain polypeptide (H3), a first light chain polypeptide (L1), a second light chain polypeptide (L2), and a third light chain polypeptide (L3) wherein, a) the first heavy chain polypeptide (H1) comprises the first variable heavy chain region (VH1); b) the second heavy chain polypeptide (H2) comprises the second variable heavy chain region (VH2); c) the third heavy chain polypeptide (H3) comprises the third variable heavy chain region (VH3); d) the first light chain polypeptide (L1) comprises the first variable light chain region (VL1); e) the second light chain polypeptide (L2) comprises the second variable light chain region (VL2); and f) the third light chain polypeptide (L3) comprises the third variable light chain region.

[0046] In some aspects, a polypeptide is fused to the N-terminus or the C-terminus of the second heavy chain polypeptide (H2), the third heavy chain polypeptide (H3), the first light chain polypeptide (L1), the second light chain polypeptide (L2), or the third light chain polypeptide (L3).

[0047] In some aspects, the polypeptide is fused via a linker peptide.

[0048] In some aspects, the polypeptide comprises CD58 or a fragment thereof.

[0049] In some aspects, the CD58 comprises the amino acid sequence of SEQ ID NO: 144. 304743675Attorney Docket No. E0701.70010WO00

[0050] In some aspects, i) the VH1 comprises the amino acid sequence of SEQ ID NO: 139; the VH2 comprises the amino acid sequence of SEQ ID NO: 145; the VH3 comprises the amino acid sequence of SEQ ID NO: 130; the VL1 comprises the amino acid sequence of SEQ ID NO: 129; the VL2 comprises the amino acid sequence of SEQ ID NO: 146; and the VL3 comprises the amino acid sequence of SEQ ID NO: 140. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] FIG.1 is schematic diagram of a multispecific antibody of the disclosure having three variable regions, each capable of binding to the same or different antigens. For example, a multispecific antibody of the disclosure can bind CD3 via a first variable region and GPRC5D via the second and third variable regions. Additionally, a multispecific antibody of the disclosure can bind CD3 via a first variable region, GPRC5D via a second variable region, and BCMA via a third variable region.

[0052] FIGs.2A-2D are exemplary schematics of multispecific antibodies against GPRC5D and CDR3. FIG.2A shows a 1:1 multispecific antibody with one arm targeting a tumor antigen (black), one arm targeting CD3 (white), and a CD58 peptide (striped oval) fused to the C-terminus of the anti-CD3 heavy chain. FIG.2B shows a 2:1 multispecific antibody with two arms targeting a tumor antigen (black), one arm targeting CD3 (white), and a CD58 peptide (striped oval) fused to the C-terminus of the heavy chain of the tumor- targeting arm. FIG.2C shows a 2:1 multispecific antibody with two arms targeting a tumor antigen (black), one arm targeting CD3 (white), and a CD58 peptide (striped oval) fused to the C-terminus of the heavy chain of the CD3-targeting arm. FIG.2D shows a 2:1 multispecific antibody with two arms targeting a tumor antigen (black), one arm targeting CD3 (white), and a CD58 peptide (striped oval) fused to the C-terminus of the light chain of the CD3-targeting arm.

[0053] FIG.3 shows binding of 1:1 and 2:1 multispecific antibodies binding to GPRC5D, as measured by enzyme-linked immunosorbent assay (ELISA). RLU = relative luminescence units.

[0054] FIGs.4A-4G relate to binding of MM.1SGFP / Luccells, MM.1Sparentalcells, and NCIH929GFPcells by 1:1 and 2:1 multispecific antibody constructs. FIG.4A shows 1:1 multispecific antibody binding to MM.1SGFP / Luccells. FIG.4B shows 2:1 multispecific antibody binding to MM.1SGFP / Luccells. FIG.4C shows 1:1 multispecific antibody binding to MM.1Sparentalcells. FIG.4D shows 2:1 multispecific antibody binding to MM.1Sparental30 304743675Attorney Docket No. E0701.70010WO00 cells. FIGs.4E and 4F show 1:1 (FIG.4E) and 2:1 (FIG.4F) multispecific antibody binding to NCIH929GFPcells. Additional assays of binding strength of 1:1 multispecific antibodies (FIG.4G) and 2:1 multispecific antibodies (FIG.4H) are shown.

[0055] FIGs.5A-5D relate to tumor cell cytotoxicity of 1:1 (FIG.5A and FIG.5B) and 2:1 (FIG.5C and FIG.5D) multispecific antibodies compared to bispecific antibodies with comparable anti-CD3 affinity in a co-culture assay of MM.1SGFPtumor cells and pan-T cells cultured at a 5:1 effector:target (E:T) ratio.

[0056] FIGs.6A-6H relate to dose-response curves of CD25+T cell frequencies as a percentage of CD4+T cells (FIGs.6A-6D) or CD8+T cells (FIGs.6E-6H) in tumor cell cytotoxicity assays of 1:1 (FIGs.6A-6B and FIGs.6E-6F) and 2:1 (FIGs.6C-6D and FIGs.6G-6H) multispecific antibody designs compared to bispecific antibodies with comparable anti-CD3 affinity in a co-culture assay of MM.1SGFPcells and pan-T cells cultured at a 5:1 E:T ratio.

[0057] FIGs.7A-7H relate to cytokine release following culture with 1:1 or 2:1 multispecific antibodies. FIGs.7A-7B show IFN-γ release (FIG.7A, 1:1 antibodies; FIG. 7B, 2:1 antibodies). FIGs.7C-7D show IL-2 release (FIG.7C, 1:1 antibodies; FIG.7D, 2:1 antibodies). FIGs.7E-7F show IL-6 release (FIG.7E, 1:1 antibodies; FIG.7F, 2:1 antibodies). FIGs.7G-7H show TNF-α release (FIG.7G, 1:1 antibodies; FIG.7H, 2:1 antibodies). DETAILED DESCRIPTION

[0058] T cell retargeting (or T cell redirecting) bispecific and multispecific antibodies are a novel class of therapeutics capable of recruiting T cells to tumor cells and inducing tumor- specific (but MHC-independent) activation of T cell effector activities. The present disclosure is directed toward T cell retargeting bispecific and multispecific antibodies containing an antigen binding domain that targets the CD3 portion of the T cell receptor protein complex for T cell recruitment and an antigen binding domain that targets T cells to a GPRC5D and / or BCMA antigen. This targeting design promotes the recruitment of T cell and positions it in close contact with a GPRC5D-expressing cell, resulting in the formation of an immunological synapse, local T cell activation, and the subsequent destruction of the target cell, such as but not limited to a cancer cell, by perforin and granzyme released from T cell cytotoxic granules into the target cell. 304743675Attorney Docket No. E0701.70010WO00

[0059] As the CD3 binding affinity of the T cell retargeting bispecific antibodies is crucial for the recruitment of T cells, the present disclosure also relates to the generation of a panel of antibodies that display different binding affinities. The affinity of the CD3 arm of a bispecific antibody can significantly modify the functional activity of the bispecific antibody. Thus, it is desirable and advantageous to have bispecific antibodies with varied affinities.

[0060] Additionally, bispecific antibodies disclosed herein may have a cytokine or costimulatory molecule fusion peptide that acts as an antagonist to inhibit or block deleterious interactions or as an agonist to mimic or enhance physiological responses. Physiological responses include but are not limited to T cell activation, T cell proliferation, T cell persistence, and prevention of T cell exhaustion. These properties are advantageous over conventional CD3-bispecific antibodies or tumor targeted co-stimulatory receptor agonists which do not optimally activate T cells and induce (or promote) T cell dysfunction. In accordance, cytokine and / or costimulatory fusion peptides are advantageous for enhancing the therapeutic potential of bispecific antibodies. In some embodiments, the costimulatory molecule of the anti-GPRC5D / anti-CD3 bispecific antibodies of the present disclosure is CD58 or a fragment thereof.

[0061] Bispecific or multispecific T cell retargeting agents of the disclosure share the drug- like properties of human monoclonal antibodies. Further, T cell retargeting bispecific and multispecific antibodies are advantageous over other existing therapies (e.g., CAR-T therapies) because they provide an off-the-shelf product with a highly favorable safety profile (e.g., mitigation of cytokine release syndrome and reduced levels of tonic signaling leading to T cell dysfunction) and the possibility of dose titration and escalation.

[0062] Also provided herein are methods of identifying a human subject having a GPRC5D expressing cancer, such as multiple myeloma, that is suitable for therapy with an anti- GPRC5D antibody or antigen binding fragment thereof. Antibody Compositions and Structures

[0063] The present disclosure provides an antibody having two antigen binding regions. In some embodiments, an antibody having two antigen binding regions comprises the following domain structure: a) a first heavy chain polypeptide (H1) comprising a variable region (VH1), and a constant region (CH1) having a constant region 1 domain (CH1H1), a hinge region (H1H), a constant region 2 domain (CH1H2) and a constant region 3 domain (CH1H3); and a 304743675Attorney Docket No. E0701.70010WO00 first light chain polypeptide (L1) comprising a variable region (VL1) and a constant region (CL1), and b) a second heavy chain polypeptide (H2) comprising a variable region (VH2), and a constant region (CH2) having a constant region 1 domain (CH2H1), a hinge region (H2H), a constant region 2 domain (CH2H2) and a constant region 3 domain (CH2H3); and second light chain polypeptide (L2) comprising a variable region (VL2) and a constant region (CL2). A schematic diagram of the antibody structure of the disclosure is shown in FIG.1. An exemplary schematic of the antibody structure with the addition of a CD58 peptide fused to the C-terminus of one of the heavy chains is shown in FIG.2A.

[0064] The present disclosure provides an antibody having three antigen binding regions. In some embodiments, an antibody having three antigen binding regions wherein each antigen binding region binds a distinct antigen. For example, a multispecific antigen binding region of the disclosure can bind CD3, GPRC5D, and BCMA wherein, the antibody has a first antigen binding region that binds CD3, a second antigen binding region that binds GPRC5D, and a third antigen binding region that binds BCMA. Bispecific and multispecific antibodies of the disclosure can optionally further comprise a CD2 ligand, such as CD58. Bispecific and multispecific antibodies of the disclosure further comprising a CD58 ligand (e.g. a CD58 polypeptide) can lead to CD2-directed costimulatory T cell activation.

[0065] In some embodiments, an antibody of the disclosure is bispecific (i.e. binds two distinct antigens) and has three antigen binding regions. In some embodiments, these antibodies are referred to as bispecific 2:1 antibodies. In some embodiments, an antibody of the disclosure is multispecific (i.e. binds three distinct antigens) and has three antigen binding regions. In some embodiments, these antibodies are referred to as multispecific 2:1 antibodies.

[0066] In some embodiments, an antibody of the disclosure that binds two distinct antigens comprises a first antigen binding region that binds a first antigen, a second antigen binding region that binds the first antigen, and a third antigen binding region that binds a second antigen. For example, a bispecific antibody of the disclosure can bind CD3 and GPRC5D wherein the antibody has a first antigen binding region that binds CD3, a second antigen binding region that binds GPRC5D, and a third antigen binding region that binds GPRC5D. For example, a bispecific antibody of the disclosure can bind CD3 and GPRC5D wherein the antibody has a first antigen binding region that binds CD3, a second antigen binding region that binds CD3, and a third antigen binding region that binds GPRC5D. For example, a bispecific antibody of the disclosure can bind CD3 and GPRC5D wherein the antibody has a 33 304743675Attorney Docket No. E0701.70010WO00 first antigen binding region that binds GPRC5D, a second antigen binding region that binds GPRC5D, and a third antigen binding region that binds CD3.

[0067] In some embodiments, the antigen binding regions of the bispecific and multispecific antibodies of the disclosure comprise a variable light chain region and a variable heavy chain region. Variable light chain regions of the disclosure comprise three complementarity determining regions (CDR) and variable heavy chain regions of the disclosure also comprise three CDRs.

[0068] In some embodiments, an antibody having three antigen binding regions comprises the following domain structure: a) a first heavy chain polypeptide (H1) comprising a first variable region (VH1), a second variable region (VH2), and a constant region (CH1) having a constant region 1 domain (CH1H1), a hinge region (H1H), a constant region 2 domain (CH1H2) and a constant region 3 domain (CH1H3); and a first light chain polypeptide (L1) comprising a variable region (VL1) and a constant region (CL1), and a second light chain polypeptide (L2) comprising a variable region (VL2) and a constant region (CL2), and b) a second heavy chain polypeptide (H2) comprising a third variable region (VH3), and a constant region (CH2) having a constant region 1 domain (CH2H1), a hinge region (H2H), a constant region 2 domain (CH2H2) and a constant region 3 domain (CH2H3); and third light chain polypeptide (L3) comprising a variable region (VL3) and a constant region (CL3).

[0069] In some embodiments, an antibody having three antigen binding regions comprises the following domain structure: a) a first heavy chain polypeptide (H1) comprising a first variable region (VH1) and a constant region (CH1) having a constant region 1 domain (CH1H1), a hinge region (H1H), a constant region 2 domain (CH1H2) and a constant region 3 domain (CH1H3); and a first light chain polypeptide (L1) comprising a variable region (VL1) and a constant region (CL1) and a constant region (CL2), and b) a second heavy chain polypeptide (H2) comprising a second variable region (VH2), a third variable region (VH3), and a constant region (CH2) having a constant region 1 domain (CH2H1), a hinge region (H2H), a constant region 2 domain (CH2H2) and a constant region 3 domain (CH2H3); and second light chain polypeptide (L2) comprising a variable region (VL2) and a constant region (CL2) and third light chain polypeptide (L3) comprising a variable region (VL3) and a constant region (CL3). Exemplary schematics of antibodies having three antigen-binding domains are shown in FIGs.2B-2D.

[0070] As used herein, the term “antibody” refers to an immunoglobulin (Ig) molecule and immunologically active portions of an immunoglobulin molecule, i.e., molecules that contain 34 304743675Attorney Docket No. E0701.70010WO00 an antigen binding site that specifically binds (immunoreacts with) an antigen. By “specifically bind” or “immunoreacts with” “or directed against” is meant that the antibody reacts with one or more antigenic determinants of the desired antigen and does not react with other polypeptides or binds at much lower affinity (Kd> 10-6). Antibodies include, but are not limited to, polyclonal antibodies, monoclonal antibodies, chimeric antibodies. The antibody may be from recombinant sources and / or produced in transgenic animals.

[0071] The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.

[0072] In general, antibody molecules obtained from humans relate to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG1, IgG2, IgG4 and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Accordingly, in one embodiment, the antibody disclosed herein is an IgG antibody.

[0073] Antibodies may be purified by well-known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol.14, No.8 (April 17, 2000), pp.25-28).

[0074] The term "antibody fragment" as used herein is intended to include without limitation, Fv, Fab, Fab', F(ab')2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, and multimers thereof, multispecific antibody fragments and Domain Antibodies. Antibodies can be fragmented using conventional techniques. For example, F(ab')2 fragments can be generated by treating the antibody with pepsin. The resulting F(ab')2 fragment can be treated to reduce disulfide bridges to produce Fab' fragments. Papain digestion can lead to the formation of Fab fragments. Fab, Fab' and F(ab')2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments and other fragments can also be synthesized by recombinant techniques. 304743675Attorney Docket No. E0701.70010WO00

[0075] Techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the disclosure (see e.g., U.S. Patent No.4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246:1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof.

[0076] As used herein, the term “epitope” refers to the site on an antigen that is recognized by the antibodies and fragments disclosed herein. The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is < 1 micromolar; e.g., < 100 nM, preferably < 10 nM and more preferably < 1 nM.

[0077] Bispecific antibodies are antibodies that have binding specificities for at least two different antigens. The present disclosure provides a bispecific antibody having a first antigen binding region that binds to a first antigen (e.g. CD3) and a second antigen binding region that binds to a second antigen (e.g. disease associated antigen such as BCMA and / or GPRC5D).

[0078] The present disclosure also provides a bispecific antibody having a first antigen binding region that binds to a first antigen (e.g. CD3) and a second antigen binding region that binds to a second antigen (e.g. disease associated antigen such as BCMA and / or GPRC5D), and a third antigen binding region that binds to the second antigen (e.g. disease associated antigen such as BCMA and / or GPRC5D).

[0079] Trispecific antibodies can be prepared. Tutt et al., J. Immunol.147:60 (1991). Antibody Variants

[0080] In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the heavy chain heterodimerization, light chain heterodimerization, binding affinity, and / or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and / or 36 304743675Attorney Docket No. E0701.70010WO00 insertions into and / or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics (e.g., light chain heterodimerization, heavy chain heterodimerization, antigen binding).

[0081] Amino acids may be grouped according to common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic (negatively charged): Asp, Glu; (4) basic (positively charged): His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe.

[0082] Functional variants of the antibody or antigen-binding fragments described herein are also encompassed by the present disclosure. The term "functional variant" as used herein includes modifications or chemical equivalents of the amino acid and nucleic acid sequences disclosed herein that perform substantially the same function as the polypeptides or nucleic acid molecules disclosed herein in substantially the same way. For example, functional variants of polypeptides disclosed herein include, without limitation, conservative amino acid substitutions.

[0083] A "conservative amino acid substitution" as used herein, is one in which one amino acid residue is replaced with another amino acid residue that change an amino acid to a different amino acid with similar biochemical properties (e.g. charge, hydrophobicity and size). Variants of polypeptides also include additions and deletions to the polypeptide sequences disclosed herein. In addition, variant nucleotide sequences include analogs and derivatives thereof. A variant of the binding proteins disclosed herein include proteins that bind to the same antigen or epitope as the binding proteins.

[0084] In some embodiments, the charged amino acid residue is a naturally occurring amino acid or a non-naturally occurring amino acid. In some embodiments, the naturally occurring charged amino acid residue is an arginine, a lysine, a histidine, a glutamic acid or an aspartic acid. Light Chain and Heavy Chain Substitution Variants

[0085] To generate a substantially homogeneous population of bispecific or multispecific antibodies with the correct pairing of heavy chain and light chains (i.e. cognate pairing or 304743675Attorney Docket No. E0701.70010WO00 heterodimerization of a light chain with the heavy chain necessary to form the variable domain or antigen binding domain of the original antibody), the first heavy chain polypeptide (H1) has a strong preference for binding with the first light chain polypeptide (L1) relative to the second light chain polypeptide (L2); and the second heavy chain polypeptide (H2) has a strong preference for binding with the second light chain polypeptide (L2) relative to first light chain polypeptide (L1). In addition, the first heavy chain polypeptide (H1) and the second heavy chain polypeptide (H2) have a stronger preference for heterodimerization than homodimerization (i.e. heavy chain heterodimerization).

[0086] Antibody variants having one or more amino acid substitutions are provided herein. Exemplary substitutional mutagenesis sites include the charged substitution pairs shown in Tables 1-6. For bispecific and multispecific antibodies of the disclosure having a heavy or light chain with more than one variable region (i.e. two antigen binding regions), the numbering of heavy and light chains substitution variants and mutations will be according to the EU and / or Kabat numbering scheme. Table 1. Kappa Light Chain and Heavy Chain – Constant Domain Mutations PairsAll position information is reported using the EU numbering scheme Wild type (WT) indicates the natural amino acid at the indicated position Charge pairs with negative and positive charge residues could be reversed between heavy and light chains, where D or E (negative charge) are replaced by K or R (positive charge) and cognate chain K or R (positive charge) are replaced by D or E (negative charge). Table 2. Kappa Light Chain and Heavy Chain – Variable Domain Mutations PairsAll position information is reported using the Kabat numbering scheme Wild type (WT) indicates the natural amino acid at the indicated position 38 304743675Attorney Docket No. E0701.70010WO00 Charged pairs with negative and positive charged residues could be reversed between heavy and light chains, where D or E (negative charged) are replaced by K or R (positive charged) and cognate chain K or R (positive charged) are replaced by D or E (negative charged). Table 3. Lambda Light Chain and Heavy Chain – Constant Domain Mutations PairsAll position information is reported using the Kabat numbering scheme Charge pairs with negative and positive charge residues could be reversed between heavy and light chains, where D or E (negative charge) are replaced by K or R (positive charge) and cognate chain K or R (positive charge) are replaced by D or E (negative charge). Table 4. Lambda Light Chain and Heavy Chain – Variable Domain Mutations PairsAll position information is reported using the Kabat numbering scheme Charge pairs with negative and positive charge residues could be reversed between heavy and light chains, where D or E (negative charge) are replaced by K or R (positive charge) and cognate chain K or R (positive charge) are replaced by D or E (negative charge). Table 5. Kappa Constant Chain Cysteine Mutation PairsAll position information is reported using the EU numbering scheme Table 6. Lambda Constant Chain Cysteine Mutation PairsAll position information is reported using the Kabat numbering scheme 304743675Attorney Docket No. E0701.70010WO00 Antibody Domain

[0087] In certain embodiments, anti-CD3 / anti-GPRC5D bispecific antibodies, anti-CD3 / anti- BCMA bispecific antibodies, and anti-CD3 / anti-GPRC5D / anti-BCMA multispecific antibodies of the present disclosure comprise antibody variants comprise substitutions in the variable heavy, variable light, constant heavy or constant light chain domains of the anti-CD3 anti-GPRC5D, anti-BCMA arms or both, as discussed in PCT Application No. PCT / US2023 / 064728 and PCT Publication No. WO2019 / 104075 A1, which are incorporated by reference herein in their entirety.

[0088] In certain embodiments, the antibody variant comprises the “light chain pairing mutation set D” comprising the following substitutions: a) the heavy chain and light chain of a first antigen binding arm comprise the following: i) the amino acid at position 39 (Kabat numbering) of the VH1 is a K and the amino acid at position 38 (Kabat numbering) of the VL1 is a D; ii) the amino acid at position 147 (EU numbering) of the CH1H1 is a K and the amino acid at position 131 (EU numbering) of the CL1 is a D; iii) the amino acid at position 173 (EU numbering) of the CH1H1 is a C and the amino acid at position 162 (EU numbering) of the CL1 is a C; iv) the amino acid at position 220 (EU numbering) in the H1H is a S and the amino acid at position 214 (EU numbering) of the CL1 is a S; and b) the heavy chain and light chain of a second antigen binding arm comprise the following: i) the amino acid at position 39 (Kabat numbering) of the VH2 is a D and the amino acid at position 38 (Kabat numbering) of the VL2 is a K; and ii) the amino acid at position 147 (EU numbering) of the CH2H1is a D and the amino acid at position 180 (EU numbering) of the CL2 is a R.

[0089] In certain embodiments, the antibody variant comprises the “light chain pairing mutation set D” comprising the following substitutions: a) the heavy chain and light chain of a first antigen binding arm comprise the following: i) the amino acid at position 39 (Kabat numbering) of the VH1 is a K and the amino acid at position 38 (Kabat numbering) of the VL1 is a D; ii) the amino acid at position 147 (EU numbering) of the CH1H1 is a K and the amino acid at position 131 (EU numbering) of the CL1 is a D; iii) the amino acid at position 173 (EU numbering) of the CH1H1 is a C and the amino acid at position 162 (EU numbering) of the CL1 is a C; iv) the amino acid at position 220 (EU numbering) in the H1H is a S and the amino acid at position 214 (EU numbering) of the CL1 is a S; and b) the heavy chain and light chain of a second antigen binding arm comprise the following: i)the amino acid at position 39 (Kabat numbering) of the VH2 is a D and the amino acid at position 38 (Kabat 304743675Attorney Docket No. E0701.70010WO00 numbering) of the VL2 is a K; and ii) the amino acid at position 147 (EU numbering) of the CH2H1 is a D and the amino acid at position 180 (EU numbering) of the CL2 is a R.

[0090] It can be desirable to modify an antibody disclosed herein with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating diseases and disorders. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and / or increased complement- mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). (See Caron et al., J Exp Med., 176:1191-1195 (1992) and Shopes, J. Immunol., 148:2918-2922. (1992)). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. (See Stevenson et al., Anti-Cancer Drug Design, 3:219-230 (1989)).

[0091] Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Patent No. 6.737,056; WO 2004 / 056312, and Shields et al., J. Biol. Chem. 9(2): 6591-6604 (2001).).

[0092] In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and / or 334 of the Fc region (EU numbering of residues).

[0093] In some embodiments, alterations are made in the Fc region that result in altered (i.e., either improved or diminished) C1q binding and / or Complement Dependent Cytotoxicity (CDC), e.g., as described in US Patent No.6,194,551 , WO 99 / 51642, and Idusogie et al. J. Immunol.164: 4178-4184 (2000).

[0094] Antibodies with increased half-lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), are described in US2005 / 0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311 , 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (US Patent No.7,371 ,826). See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No.5,648,260; U.S. Patent No.5,624,821 ; and WO 94 / 29351 concerning other examples of Fc region variants. 304743675Attorney Docket No. E0701.70010WO00

[0095] In some embodiments, antibodies may comprise a substitution mutation in the Fc region that reduces effector function. In some embodiments, the substitution mutation is an aglycosylation site mutation. In some embodiments, the aglycosylation site mutation is at amino acid residue 297 and amino acid substitutions at residues 234, 235, 265 and 331 (EU numbering) to disrupt the Fc receptor binding interface. In some embodiments, the aglycosylation site mutation reduces effector function of the antibody.

[0096] In some embodiments, i) the H1H and / or the H2H has an A at positions 234 and 235 (EU numbering); or ii) the H1H and / or the H2H has an A at positions 234, 235 and 237 (EU numbering) iii) the H1H and / or the H2H has an A at positions 234 and 235 and G at position 329 (EU numbering). In some embodiments, i) the CH1H2and / or the CH2H2has an A at position 297 (EU numbering); ii) the CH1H2and / or the CH2H2has a G at position 297 (EU numbering); iii) the CH1H2 and / or the CH2H2 has a Q at position 297 (EU numbering); or iv) the CH1H2 and / or the CH2H2 has a S at position 297 (EU numbering). In some embodiments, the CH1H2and / or the CH2H2has an S at position 331 (EU numbering).

[0097] In some embodiments, the CH1H2 and / or the CH2H2 has an A at position 299 (EU numbering) so that N-linked glycosylation is eliminated thus abrogating effector function.

[0098] The use of knobs into holes as a method of producing multispecific antibodies is well known in the art. See U.S. Pat. No.5,731,168 granted 24 Mar.1998 assigned to Genentech, PCT Pub. No. WO2009089004 published 16 Jul.2009 and assigned to Amgen, and US Pat. Pub. No.20090182127 published 16 Jul.2009 and assigned to Novo Nordisk A / S. See also Marvin and Zhu, Acta Pharmacologica Sincia (2005) 26(6):649-658 and Kontermann (2005) Acta Pharacol. Sin., 26:1-9.

[0099] A “protuberance” refers to at least one amino acid side chain which projects from the interface of a first polypeptide and is therefore positionable in a compensatory cavity in the adjacent interface (i.e. the interface of a second polypeptide) so as to stabilize the heteromultimeric antibody, and thereby favor heteromultimeric antibody formation over homomultimeric antibody formation, for example. The protuberance may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface). Normally, nucleic acid encoding the interface of the first polypeptide is altered to encode the protuberance. To achieve this, the nucleic acid encoding at least one “original” amino acid residue in the interface of the first polypeptide is replaced with nucleic acid encoding at least one “import” amino acid residue which has a larger side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original 42 304743675Attorney Docket No. E0701.70010WO00 and corresponding import residue. The upper limit for the number of original residues which are replaced is the total number of residues in the interface of the first polypeptide.

[0100] The preferred import residues for the formation of a protuberance are generally naturally occurring amino acid residues and are preferably selected from arginine (R), phenylalanine (F), tyrosine (Y) and tryptophan (W). Most preferred are tryptophan and tyrosine. In one embodiment, the original residue for the formation of the protuberance has a small side chain volume, such as alanine, asparagine, aspartic acid, glycine, serine, threonine or valine. Exemplary amino acid substitutions in the CH1H3 or CH2H3 domain for forming the protuberance include without limitation the T366W substitution.

[0101] A “cavity” refers to at least one amino acid side chain which is recessed from the interface of a second polypeptide and therefore accommodates a corresponding protuberance on the adjacent interface of a first polypeptide. The cavity may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface). Normally, nucleic acid encoding the interface of the second polypeptide is altered to encode the cavity. To achieve this, the nucleic acid encoding at least one “original” amino acid residue in the interface of the second polypeptide is replaced with DNA encoding at least one “import” amino acid residue which has a smaller side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original and corresponding import residue. The upper limit for the number of original residues which are replaced is the total number of residues in the interface of the second polypeptide. The preferred import residues for the formation of a cavity are usually naturally occurring amino acid residues and are preferably selected from alanine (A), serine (S), threonine (T) and valine (V). Most preferred are serine, alanine or threonine. In one embodiment, the original residue for the formation of the cavity has a large side chain volume, such as tyrosine, arginine, phenylalanine or tryptophan. Exemplary amino acid substitutions in the CH1H3 or CH2H3 domain for generating the cavity include without limitation the T366S, L368A, Y407A, Y407T and Y407V substitutions. In certain embodiments, the knob half-antibody comprises T366W substitution, and the hole half-antibody comprises the T366S / L368A / Y407V substitutions.

[0102] In certain embodiments, the antibody variant comprises the following substitutions: the CH1H3has a C at position 349, an S at position 366, an A at position 368 and a V at position 407 (EU numbering); and the CH2H3 has a C at position 354 and a W at position 366 (EU numbering). 304743675Attorney Docket No. E0701.70010WO00

[0103] In certain embodiments, the antibody variant comprises the following substitutions: the CH2H3 has a C at position 349, an S at position 366, an A at position 368 and a V at position 407 (EU numbering); and the CH1H3 has a C at position 354 and a W at position 366 (EU numbering).

[0104] In certain embodiments, the antibody variant comprises the following substitutions: the CH1H3 has a C at position 354, an S at position 366, an A at position 368 and a V at position 407 (EU numbering); and the CH2H3has a C at position 349 and a W at position 366 (EU numbering).

[0105] In certain embodiments, the antibody variant comprises the following substitutions: the CH2H3has a C at position 354, an S at position 366, an A at position 368 and a V at position 407 (EU numbering); and the CH1H3has a C at position 349 and a W at position 366 (EU numbering). Cluster of Differentiation 3 (CD3)

[0106] The present disclosure provides bispecific antibodies comprising a first antigen binding domain that binds to a CD3 antigen expressed on a T cell, and a second antigen binding domain that binds to a GPRC5D antigen on the surface of a cancer cell. The present disclosure also provides bispecific antibodies comprising a first antigen binding domain that binds to a CD3 expressed on a T cell, and a second and third antigen binding domain that binds to a GPRC5D antigen on the surface of a cancer cell. The present disclosure also provides multispecific antibodies comprising a first antigen binding domain that binds to a CD3 antigen expressed on a T cell, and a second antigen binding domain that binds to a BCMA antigen on the surface of a cancer cell and a third antigen binding domain that binds to a GPRC5D antigen on the surface of a cancer cell.

[0107] Antibodies of the disclosure are useful, for example, for treating or delaying the progression of a cell proliferative disorder (e.g., cancer expressing GPRC5D and / or BCMA).

[0108] The term “cluster of differentiation 3” or “CD3,” as used herein, refers to any native CD3 from any vertebrate source, including mammals such as primates (e.g. humans, cynomolgus monkey) and rodents (e.g., mice and rats), unless otherwise indicated, including, for example, CD3ε, CD3γ, CD3ζ,and CD3δ. CD3 is a cell surface complex expressed on T cells in association with the T cell receptor. The CD3 complex is required for the activation of CD8+ and CD4+ T lymphocytes. It is formed of three different but highly related chains: one CD3 gamma chain, one CD3 delta chain, and two CD3 epsilon chains, which associate 44 304743675Attorney Docket No. E0701.70010WO00 with each other to form a CD3 epsilon / gamma heterodimer, and a CD3 epsilon / delta heterodimer. The two CD3 heterodimers, together with the T cell receptor (TCR) and the signal-transducing zeta chain homodimer form the T cell receptor complex.

[0109] The term encompasses “full-length” unprocessed CD3 (e.g., unprocessed or unmodified CD3ε or CD3γ), as well as any form of CD3 that results from processing in the cell. The term also encompasses naturally occurring variants of CD3, including, for example, splice variants or allelic variants. CD3 includes, for example, human CD3ε protein (NCBI RefSeq No. NP_000724), which is 207 amino acids in length.

[0110] In some embodiments, the disclosure provides isolated antibodies that bind to CD3. In some embodiments, the disclosure provides antibodies that bind to CD3ε. In some instances the anti-CD3ε antibody binds to a human CD3ε polypeptide or a cynomolgus monkey (cyno) CD3ε polypeptide. In some instances, the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3ε polypeptide (SEQ ID NO: 419) or a cyno CD3ε polypeptide (SEQ ID NO: 420), respectively. In some instances, the anti-CD3 antibody binds to an epitope within a fragment of CD3ε (e.g., human CD3ε) consisting of amino acid residues 1-26 or amino acid residues 1-27 of human CD3ε (SEQ ID NO: 419).

[0111] A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (1989) Science, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex is used to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.

[0112] In some embodiments, alanine scanning mutagenesis was performed on the “SP34” anti-CD3ε antibody to produce affinity modulated anti-CD3ε antibodies of the disclosure.

[0113] In some embodiments, the first antigen binding region that binds to CD3 comprises any one of the VH and VL sequences listed in Table 7. In Table 7, the underlined sequences are CDR sequence according to Kabat and the bolded sequences are CDR sequences 304743675Attorney Docket No. E0701.70010WO00 according to Chothia.

[0114] In some embodiments, an anti-CD3 antibody of the disclosure comprises: a) a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (VHCDR1), a VH complementarity determining region 2 (VHCDR2) and a VH complementarity determining region 3 (VHCDR3); and b) a light chain variable region (VL) comprising a VL complementarity determining region 1 (VLCDR1), a VL complementarity determining region 2 (VLCDR2) and a VL complementarity determining region 3 (VLCDR3). Tables 8 and 9 provide exemplary CDR sequences of the anti-CD3 antibodies provided herein (CDR sequences are determined according to Kabat). Table 7. Anti-CD3 Variable Heavy Chain and Variable Light Chain Domains304743675Attorney Docket No. E0701.70010WO00Table 8. Anti-CD3 Heavy Chain CDRsTable 9. Anti-CD3 Light Chain CDRs304743675Attorney Docket No. E0701.70010WO00

[0115] Provided herein are bispecific and multispecific antibodies comprising a first antigen binding domain that binds a first antigen (e.g. CD3) and a second antigen binding domain that binds to a second antigen (e.g. GPRC5D and / or BCMA). In some embodiments the bispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a variable region (VH1), and a constant region (CH1) having a constant region 1 domain (CH1H1), a hinge region (H1H), a constant region 2 domain (CH1H2) and a constant region 3 domain (CH1H3); and a first light chain polypeptide (L1) comprising a variable region (VL1) and a constant region (CL1), and a second heavy chain polypeptide (H2) comprising a variable region (VH2), and a constant region (CH2) having a constant region 1 domain (CH2H1), a hinge region (H2H), a constant region 2 domain (CH2H2) and a constant region 3 domain (CH2H3); and second light chain polypeptide (L2) comprising a variable region (VL2) and a constant region (CL2).

[0116] In some embodiments, the bispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a second variable heavy region (VH2), a second light chain polypeptide (L2) comprising a second variable light region (VL2), wherein the first antigen binding domain comprises VL1 and VH1 and the second antigen binding domain comprises VL2 and VH2, and wherein the first antigen binding domain binds CD3 and the second antigen binding domain binds GPRC5D or BCMA.

[0117] In some embodiments, a 2:1 bispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a second variable heavy region (VH2), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a third variable heavy region (VH3), a second light chain polypeptide (L2) comprising a second variable light region (VL2), and a third light chain polypeptide (L3) comprising a third variable light region (VL3) 304743675Attorney Docket No. E0701.70010WO00 wherein the first antigen binding domain comprises VL1 and VH1, the second antigen binding domain comprises VL2 and VH2, the third antigen binding region comprises VL3 and VH3 and wherein the first antigen binding domain binds one of CD3 or GPRC5D, the second antigen binding domain binds one of CD3 or GPRC5D, and the third antigen binding domain binds one of CD3 or GPRC5D.

[0118] In some embodiments, a 2:1 bispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a second variable heavy region (VH2), a third variable heavy region (VH3), a second light chain polypeptide (L2) comprising a second variable light region (VL2), and a third light chain polypeptide (L3) comprising a third variable light region (VL3) wherein the first antigen binding domain comprises VL1 and VH1, the second antigen binding domain comprises VL2 and VH2, the third antigen binding region comprises VL3 and VH3 and wherein the first antigen binding domain binds one of CD3 or GPRC5D, the second antigen binding domain binds one of CD3 or GPRC5D, and the third antigen binding domain binds one of CD3 or GPRC5D.

[0119] In some embodiments, a 2:1 multispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a second variable heavy region (VH2), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a third variable heavy region (VH3), a second light chain polypeptide (L2) comprising a second variable light region (VL2), and a third light chain polypeptide (L3) comprising a third variable light region (VL3) wherein the first antigen binding domain comprises VL1 and VH1, the second antigen binding domain comprises VL2 and VH2, the third antigen binding region comprises VL3 and VH3 and wherein the first antigen binding domain binds one of CD3, GPRC5D, or BCMA, the second antigen binding domain binds one of CD3, GPRC5D, or BCMA, and the third antigen binding domain binds one of CD3, GPRC5D, or BCMA.

[0120] In some embodiments, a 2:1 multispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a second variable heavy region (VH2), a third variable heavy region (VH3), a second light chain polypeptide (L2) comprising a second variable light region (VL2), and a third light chain polypeptide (L3) comprising a third variable light region (VL3) 49 304743675Attorney Docket No. E0701.70010WO00 wherein the first antigen binding domain comprises VL1 and VH1, the second antigen binding domain comprises VL2 and VH2, the third antigen binding region comprises VL3 and VH3 and wherein the first antigen binding domain binds one of CD3, GPRC5D, or BCMA, the second antigen binding domain binds one of CD3, GPRC5D, or BCMA, and the third antigen binding domain binds one of CD3, GPRC5D, or BCMA.

[0121] In some embodiments, the bispecific and multispecific antibodies of the disclosure comprises an antigen binding domain (e.g. binding to CD3) comprising any one of the VH1 and VL1 sequences listed in Table 7.

[0122] Tables 8 and 9 provide exemplary CDR sequences of the anti-CD3 antibodies provided herein.

[0123] In some embodiments, the bispecific antibody comprises any one of the anti-CD3 antibodies of the disclosure.

[0124] In some embodiments, the binding affinity (KD) of the first antigen binding region of the bispecific antibody that binds to CD3 (e.g., human CD3ε (e.g., (SEQ ID NO: 419) or cynomolgus CD3ε (e.g., (SEQ ID NO: 422)) is about 0.001 nM to about 5000 nM. In some embodiments, the binding affinity to CD3 is about 0.001 nM to about 0.01 nM, about 0.01 to about 0.1 nM or about 0.1 to about 1nM. In some embodiments, the binding affinity is about 1 nM to about 1000 nM, about 10 nM to about 1000 nM or about 100nM to about 1000 nM.

[0125] In some embodiments, the binding affinity is about 50 nM to about 5000 nM, about 50 nM to about 4000 nM, about 50 nM to about 3000 nM, about 50 nM to about 2000 nM, about 50 nM to about 1000 nM, about 50 nM to about 900 nM, about 50 nM to about 800 nM, about 50 nM to about 700 nM, about 50 nM to about 600 nM, about 50 nM to about 500 nM, about 50 nM to about 400 nM, about 50 nM to about 300 nM, about 50 nM to about 200 nM, about 50 nM to about 100 nM or about 50 nM to about 500 nM. In some embodiments, the binding affinity is about 50 nM to about 200 nM.

[0126] In some embodiments, the binding affinity is about 10 nM to about 20 nM, about 20 nM to about 30 nM, about 30 nM to about 40 nM, about 50 nM to about 60 nM, about 60 nM to about 70 nM, about 70 nM to about 80 nM, about 80 nM to about 90 nM, about 90 nM to about 100 nM, about 100 nM to about 110 nM, about 110 nM to about 120 nM, about 120 nM to about 130 nM, about 130 nM to about 140 nM, about 150 nM to about 160 nM, about 160 nM to about 170 nM, about 170 nM to about 180 nM, about 180 nM to about 190 nM, or about 190 nM to about 200 nM. 304743675Attorney Docket No. E0701.70010WO00

[0127] In some embodiments, the binding affinity is less than about 5000 nM, 4000 nM, 3000 nM, 2000 nM, 1000 nM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 275 nM, 250 nM, 225 nM, 200 nM, 175 nM, 150 nM, 125 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9.5 nM, 9nM, 8.5 nM, 8 nM, 7.5 nM, 7 nM, 6.5 nM, 6 nM, 5 nM, 4.5 nM, 4 nM, 3.5 nM, 3 nM, 2.5 nM, 2 nM, 1.5 nM, 1 nM, or 0.5 nM. GPRC5D Antigen

[0128] The present disclosure provides bispecific and multispecific antibodies comprising an antigen binding domain that binds to a CD3 expressed on a T cell, and an antigen binding domain that binds to a GPRC5D antigen on the surface of a cancer cell. Antibodies of the disclosure are useful, for example, for treating or delaying the progression of a cell proliferative disorder (e.g., cancer expressing GPRC5D).

[0129] G-protein coupled receptor, class C, group 5, member D (GPRC5D) is an orphan, atypical, class C GPCR first identified in 2001 (Bräuner-Osborne et al. Biochim Biophys Acta. 1518(3):237-248, 2001). GPRC5D and other group 5 GPCRs have unusually short amino-terminal domains for class C receptors, and are therefore, predicted to be conformationally similar to class A receptors. In this regard they are unique, with sequence homology to class C GPCRs and predicted structural topology comparable to class A receptors. Functional consequence of GPRC5D activation has not been described and the ligand remains unknown. The gene has three exons and is located on chromosome 12p13.3 in humans. GPRC5D receptor is highly conserved among various species and shares 92% identity with cynomolgus monkey GPRC5D.

[0130] GPRC5D mRNA is predominantly expressed in all malignant plasma cells from multiple myeloma patients (Atamaniuk J A et al. Eur J Clin Invest 42(9) 953-960; 2012; Frigyesi-blood and Cohen, et al. Hematology 18(6): 348-35; 2013). GPRC5D expression is variable among the patients and correlate well with plasma cell burden and genetic aberrations such as Rb-1 deletion (Atamaniuk J A et al. Eur J Clin Invest 42(9) 953-960; 2012).

[0131] Hence, targeting of GPRC5D has been proposed for the treatment of cancer.

[0132] The terms “GPRC5D” and “GPRC5D antigen” are used interchangeably herein, and include any variants, isoforms and species homologs of human GPRC5D which are naturally expressed by cells or are expressed on cells transfected with the GPRC5D gene. Binding of an antibody of the disclosure to the GPRC5D antigen mediate the killing of cells expressing 51 304743675Attorney Docket No. E0701.70010WO00 GPRC5D (e.g., a tumor cell) by inactivating GPRC5D. The killing of the cells expressing GPRC5D may occur by one or more of the following mechanisms: Cell death / apoptosis induction, ADCC and CDC.

[0133] The term “anti-GPRC5D antibody” according to the disclosure is an antibody that binds specifically to GPRC5D antigen.

[0134] This disclosure provides bispecific and multispecific antibodies comprising a binding region that binds CD3 and a binding region that binds GPRC5D.

[0135] In some embodiments the bispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a variable region (VH1), and a constant region (CH1) having a constant region 1 domain (CH1H1), a hinge region (H1H), a constant region 2 domain (CH1H2) and a constant region 3 domain (CH1H3); and a first light chain polypeptide (L1) comprising a variable region (VL1) and a constant region (CL1), and a second heavy chain polypeptide (H2) comprising a variable region (VH2), and a constant region (CH2) having a constant region 1 domain (CH2H1), a hinge region (H2H), a constant region 2 domain (CH2H2) and a constant region 3 domain (CH2H3); and second light chain polypeptide (L2) comprising a variable region (VL2) and a constant region (CL2).

[0136] In some embodiments, the bispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a second variable heavy region (VH2), a second light chain polypeptide (L2) comprising a second variable light region (VL2), wherein the first antigen binding domain comprises VL1 and VH1 and the second antigen binding domain comprises VL2 and VH2, and wherein the first antigen binding domain binds CD3 and the second antigen binding domain binds GPRC5D or BCMA.

[0137] In some embodiments, a 2:1 bispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a second variable heavy region (VH2), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a third variable heavy region (VH3), a second light chain polypeptide (L2) comprising a second variable light region (VL2), and a third light chain polypeptide (L3) comprising a third variable light region (VL3) wherein the first antigen binding domain comprises VL1 and VH1, the second antigen binding domain comprises VL2 and VH2, the third antigen binding region comprises VL3 and VH3 and wherein the first antigen binding domain binds one of CD3 or GPRC5D, the second 304743675Attorney Docket No. E0701.70010WO00 antigen binding domain binds one of CD3 or GPRC5D, and the third antigen binding domain binds one of CD3 or GPRC5D.

[0138] In some embodiments, a 2:1 bispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a second variable heavy region (VH2), a third variable heavy region (VH3), a second light chain polypeptide (L2) comprising a second variable light region (VL2), and a third light chain polypeptide (L3) comprising a third variable light region (VL3) wherein the first antigen binding domain comprises VL1 and VH1, the second antigen binding domain comprises VL2 and VH2, the third antigen binding region comprises VL3 and VH3 and wherein the first antigen binding domain binds one of CD3 or GPRC5D, the second antigen binding domain binds one of CD3 or GPRC5D, and the third antigen binding domain binds one of CD3 or GPRC5D.

[0139] In some embodiments, a 2:1 multispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a second variable heavy region (VH2), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a third variable heavy region (VH3), a second light chain polypeptide (L2) comprising a second variable light region (VL2), and a third light chain polypeptide (L3) comprising a third variable light region (VL3) wherein the first antigen binding domain comprises VL1 and VH1, the second antigen binding domain comprises VL2 and VH2, the third antigen binding region comprises VL3 and VH3 and wherein the first antigen binding domain binds one of CD3, GPRC5D, or BCMA, the second antigen binding domain binds one of CD3, GPRC5D, or BCMA, and the third antigen binding domain binds one of CD3, GPRC5D, or BCMA.

[0140] In some embodiments, a 2:1 multispecific antibody has the following structure: a first heavy chain polypeptide (H1) comprising a first variable heavy region (VH1), a first light chain polypeptide (L1) comprising a first variable light region (VL1), second heavy chain polypeptide (H2) comprising a second variable heavy region (VH2), a third variable heavy region (VH3), a second light chain polypeptide (L2) comprising a second variable light region (VL2), and a third light chain polypeptide (L3) comprising a third variable light region (VL3) wherein the first antigen binding domain comprises VL1 and VH1, the second antigen binding domain comprises VL2 and VH2, the third antigen binding region comprises VL3 and VH3 and wherein the first antigen binding domain binds one of CD3, GPRC5D, or BCMA, the 53 304743675Attorney Docket No. E0701.70010WO00 second antigen binding domain binds one of CD3, GPRC5D, or BCMA, and the third antigen binding domain binds one of CD3, GPRC5D, or BCMA.

[0141] For example, the antigen binding region that binds to GPRC5D can be derived from the binding regions of an anti-GPRC5D antibody. Exemplary anti-GPRC5D antibodies include but are not limited to forimtamig (RG6234; F. Hoffmann-La Roche), talquetamab (Talvey; CAS 2226212-40-2; Janssen), and / or BGCB491 and those described in PCT Publications WO2022175255A2, WO2018017786A2, US2019 / 0367612A1, WO2022 / 025220A1, WO2021 / 018859A2, US2021 / 0393689A1, and US10590196B2 each of which are incorporated herein in their entireties.

[0142] In some embodiments, an antigen binding region that binds GPRC5D comprises any one of the VH and VL sequences listed in Table 10.

[0143] In some embodiments, a binding region that binds to GPRC5D comprises: a) a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (VHCDR1), a VH complementarity determining region 2 (VHCDR2) and a VH complementarity determining region 3 (VHCDR3); and b) a light chain variable region (VL) comprising a VL complementarity determining region 1 (VLCDR1), a VL complementarity determining region 2 (VLCDR2) and a VL complementarity determining region 3 (VLCDR3). Tables 11 and 12 provide exemplary CDR sequences of the anti- GPRC5D antibodies (CDR sequences are determined according to Kabat). Table 10. Anti-GPRC5D Variable Heavy Chain and Variable Light Chain Domains304743675Attorney Docket No. E0701.70010WO00Table 11. Anti-GPRC5D Heavy Chain CDRsTable 12. Anti-GPRC5D Light Chain CDRs

[0144] The present disclosure provides bispecific and multispecific antibodies comprising an antigen binding domain that binds to a CD3 expressed on a T cell, and an antigen binding domain that binds to a GPRC5D antigen on the surface of a cancer cell. Antibodies of the disclosure are useful, for example, for treating or delaying the progression of a cell proliferative disorder (e.g., cancer expressing GPRC5D).

[0145] B-cell maturation antigen, also known as BCMA, CD269, TNFRSF17 (UniProt Q02223), is a member of the tumor necrosis receptor superfamily that is preferentially expressed in differentiated plasma cells [Laabi et al. (1992) EMBO J 11(11):3897-3904; Madry et al. (1998) Int Immunol 10(11):1693-1702]. BCMA is a non-glycosylated type I transmembrane protein, which is involved in B cell maturation, growth and survival. BCMA is a receptor for two ligands of the TNF superfamily: APRIL (a proliferation-inducing ligand, CD256, TNFSF13), the high-affinity ligand to BCMA, and the B cell activation factor BAFF (THANK, BlyS, B lymphocyte stimulator, TALL-1 and zTNF4), the low-affinity ligand to 304743675Attorney Docket No. E0701.70010WO00 BCMA. APRIL and BAFF show structural similarity and overlapping yet distinct receptor binding specificity. The negative regulator TACI also binds to both BAFF and APRIL. The coordinate binding of APRIL and BAFF to BCMA and / or TACI activates transcription factor NF-xB and increases the expression of pro-survival Bcl-2 family members (e.g. Bcl-2, Bcl- xL, Bcl-w, Mcl-1, A1) and down regulates expression of pro-apoptotic factors (e.g. Bid, Bad, Bik, Bim, etc.), thus inhibiting apoptosis and promoting survival. This combined action promotes B cell differentiation, proliferation, survival and antibody production (as reviewed in Rickert R C et al., Immunol Rev (2011) 244 (1): 115-133). In line with this finding, BCMA also supports growth and survival of malignant human B cells, including multiple myeloma (MM) cells. Novak et al. found that MM cell lines and freshly isolated MM cells express BCMA and TACI protein on their cell surfaces and have variable expression of BAFF-R protein on their cell surface (Novak et al., (2004) Blood 103(2):689-694).

[0146] The use of anti-BCMA antibodies for the treatment of lymphomas and multiple myeloma are mentioned in WO2002066516 and WO2010104949. Antibodies against BCMA are described e.g. in Gras M-P. et al. Int Immunol.7 (1995) 1093-1106, WO200124811, and WO200124812. Nevertheless, despite the fact that BCMA, BAFF-R and TACI, i.e., B cell receptors belonging to the TNF receptor superfamily, and their ligands BAFF and APRIL are subject to therapies in fighting against cancer, further options for the treatment of such medical conditions are needed. Table 13. Anti-BCMA Variable Heavy Chain and Variable Light Chain DomainsTable 14. Anti-BCMA Heavy Chain CDRsTable 15. Anti-BCMA Light Chain CDRs

[0147] In some embodiments, a binding region that binds to BCMA comprises: a) a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (VHCDR1), a VH complementarity determining region 2 (VHCDR2) and a VH complementarity 304743675Attorney Docket No. E0701.70010WO00 determining region 3 (VHCDR3); and b) a light chain variable region (VL) comprising a VL complementarity determining region 1 (VLCDR1), a VL complementarity determining region 2 (VLCDR2) and a VL complementarity determining region 3 (VLCDR3). Tables 14 and 15 provide exemplary CDR sequences of the anti-GPRC5D antibodies. Fusion Peptides

[0148] Provided herein is an antibody (e.g. monospecific antibody or bispecific antibody) that has a fusion peptide fused to the N-terminus or the C-terminus of the first heavy chain polypeptide or the second heavy chain polypeptide.

[0149] Critical to the initial T cell response is the capacity for T cells to detect foreign and mutated proteins through their T cell receptor. This response, often referred to as signal 1 of T cell activation, occurs when the T cell receptor engages a cell that displays a foreign or mutated protein fragment or antigen in a specific protein complex called the Major Histocompatibility Complex I (MHCI). The activation of the T cell receptor is by itself both activating and auto-regulatory to T cells. Strong binding of the TCR to an MHCI complex creates chronic activation of the TCR. This form of signal is associated with T cells that are reactive to self-antigens. T cells are programed to inactivate when they experience this form activation. T cells with TCR that bind weaker, but sufficient for activation, experience acute signaling with the potential to remain active and differentiate into memory T cells. This is emerging as important consideration in the design the T cell therapeutics.

[0150] T cell cytokine activation, often referred to signal 3, is important in T cell transitions, either from non-dividing to a state of rapid cell division or from one phenotypic state to another. T cell cytokine receptors bind to cytokines that are produced by immune and non- immune cells and depending on the cytokine and the state of the T cell at the time of receiving the cytokine signal can induce cell proliferation, can sustain vitality, or can induce differentiation of T cells into a specialized cell state appropriate for sustained activation or inactivation following infection.

[0151] One example is the transition that naïve cells experience through cytokines which can induce naïve T cells to proliferate and promote T cell differentiation into memory T cells. Exemplary cytokines include but are not limited to IL-2, IL-7, IL-10, IL-12, IL-15, IL-18 and IL-21.

[0152] Costimulatory receptor activation, referred to as signal 2 provides a context specific cell-to-cell reinforcement of T activation. The most recognized form of costimulation occurs 304743675Attorney Docket No. E0701.70010WO00 when T cells interact with activated antigen presenting cells through the T cell costimulatory receptor CD28 with CD80 and CD86 ligands found on APCs. These interactions can “prime” specific T cells armed with T cell receptors responsive to pathogen or cancer proteins.

[0153] Less appreciated is costimulation induced at the site of infection and malignancies. This includes costimulation that acts through CD2 and NKG2D receptors responsive to ligands like CD58 and UL16 binding proteins (e.g. ULBP2 / 5 / 6) that are induced in immune cells and epithelial cells upon viral infection. These signals provide not only reinforcement of T activation, but confirmation that the T cell’s lethal effector activities are targeted with single cell accuracy. While many costimulatory receptors have been discovered, the importance of each receptor’s specific context and the impact of concurrent signaling of multiple costimulatory receptors remains largely unknown and an area to greatly advance our understanding of T cell biology and creating possibilities for novel tumor-targeted T cell therapeutic development.

[0154] Costimulatory ligands include but are not limited to CD48, CD58, CD86, TNFSF9, OX40L, 4-1BBL, GITL, CD70, CD80, MR1, TNFSF4, ICOSL or ICOSLG.

[0155] CD58 is advantageous over other costimulatory ligands in that it is the primary costimulatory pathway available at the tumor site as tumor infiltrating T lymphocytes often lose expression of other costimulatory receptors like CD28, or due to the low immunogenicity of tumor cells, tumor cells do not sufficiently activate T cell, thus limiting the potential of inducible costimulatory receptors like 41BB.

[0156] As described previously, the anti-CD3ε antibodies of the disclosure induce varying levels of T cell receptor activation that confer alteration in T cell vitality and cytokine production. Accordingly, a fusion of the costimulatory ligand CD58 to the anti-CD3ε bispecific antibody provides integrated costimulatory T cell activation via CD2 binding for optimal T cell activation.

[0157] In some embodiments, the bispecific or multispecific antibody has a peptide fused to the N-terminus of the first heavy chain polypeptide (H1). In some embodiments, the bispecific or multispecific antibody has a peptide fused to the C-terminus of the first heavy chain polypeptide (H1). In some embodiments, the bispecific or multispecific antibody has a polypeptide fused to the N-terminus of the second heavy chain polypeptide (H2). In some embodiments, the bispecific or multispecific antibody has a peptide fused to the C-terminus of the second heavy chain polypeptide (H2). In some embodiments, the bispecific or multispecific antibody has a peptide fused to the N-terminus of the first light chain 304743675Attorney Docket No. E0701.70010WO00 polypeptide (L1). In some embodiments, the bispecific or multispecific antibody has a peptide fused to the C-terminus of the first light chain polypeptide (L1). In some embodiments, the bispecific or multispecific antibody has a polypeptide fused to the N-terminus of the second light chain polypeptide (L2). In some embodiments, the bispecific or multispecific antibody has a peptide fused to the C-terminus of the second light chain polypeptide (L2). In some embodiments, the bispecific or multispecific antibody has a polypeptide fused to the N- terminus of the third light chain polypeptide (L3). In some embodiments, the bispecific or multispecific antibody has a peptide fused to the C-terminus of the third light chain polypeptide (L3). Exemplary peptides include but are not limited to IL-2, IL-7, IL-10, IL-12, IL-15, IL-18, IL-21 or portions thereof. Exemplary peptides include but are not limited to CD48, CD58, CD86, TNFSF9, OX40L, 4-1BBL, GITL, CD70, CD80, MR1, TNFSF4, ICOSL, ICOSLG or portions thereof. Exemplary peptide sequences that are fused to the bispecific antibodies include but are not limited to those listed in Table 14.1 and Table 14.2. Table 14.1. Exemplary Fusion Peptide SequencesTable 14.2. Exemplary Fusion Peptide Sequences59 304743675Attorney Docket No. E0701.70010WO00

[0158] In some embodiments the polypeptide is fused directly to the bispecific antibody. In some embodiments, the polypeptide is fused indirectly through a linker. In some embodiments, the bispecific antibody fused with a peptide comprises a linker sequence. Exemplary linker sequences include but are not limited to those listed in Table 15.1 and Table 15.2. Table 15.1. Exemplary Linker SequencesTable.15.2 Exemplary Linker Sequences60 304743675Attorney Docket No. E0701.70010WO00Exemplary Bispecific and Multispecific Antibodies That Bind to CD3, GPRC5D, and / or BCMA

[0159] Provided herein are bispecific and multispecific antibodies comprising an antigen binding domain that binds a first antigen (e.g. CD3) and a second antigen binding domain that binds to a GPRC5D and / or BCMA. Provided herein multispecific antibodies comprising 304743675Attorney Docket No. E0701.70010WO00 an antigen binding domain that binds a first antigen (e.g. CD3); a second antigen binding domain that binds to a GPRC5D and / or BCMA; and a third antigen binding domain that binds GPRC5D and / or BCMA.

[0160] Tables 8 and 9 provide exemplary CDR sequences of the anti-CD3ε antibodies provided herein. Tables 11 and 12 provide exemplary CDR sequences of the anti-GPRC5D antibodies provided herein. Tables 14 and 15 provide exemplary CDR sequences of the anti- BCMA antibodies provided herein.

[0161] In some embodiments, the bispecific or multispecific antibody of the disclosure comprises a first antigen binding domain (e.g. binding to CD3) comprising any one of the VH and VL sequences listed in Table 7 and a second antigen binding domain (e.g. binding to GPRC5D and / or BCMA) comprising any one of the VH and VL sequences listed in Table 10 and Table 13.

[0162] In some embodiments, the bispecific and multispecific antibodies of the disclosure comprises a first heavy chain polypeptide (H1) and a first light chain polypeptide (L1); and a second heavy chain polypeptide (H2); a second light chain polypeptide (L2) and / or a third light chain (L3) comprising any one of the sequence listed in Table 16, Table 17 and Table 18.

[0163] In some embodiments, the bispecific and multispecific antibodies of the disclosure provided herein comprises a H1 that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% identical to the amino acid sequence of the sequences listed in Table 16, Table 17 and Table 18. In some embodiments, the H1 comprises a C-terminal lysine (K) residue.

[0164] In some embodiments, the bispecific and multispecific antibodies of the disclosure provided herein comprises a L1 that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% identical to the amino acid sequence of the sequences listed in Table 16, Table 17 and Table 18.

[0165] In some embodiments, the bispecific and multispecific antibodies of the disclosure provided herein comprises a H2 that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% identical to the amino acid sequence of the sequences listed in Table 16, Table 17 and Table 18. In some embodiments, the H1 comprises a C-terminal lysine (K) residue.

[0166] In some embodiments, the bispecific and multispecific antibodies of the disclosure 62 304743675Attorney Docket No. E0701.70010WO00 provided herein comprises a L2 that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% identical to the amino acid sequence of the sequences listed in Table 16, Table 17 and Table 18. Table 16. Exemplary Bispecific Antibodies that bind CD3ε and GPRC5D63 304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO0071 304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO0075 304743675Attorney Docket No. E0701.70010WO00Table 17. Exemplary 2:1 Antibodies that bind CD3 and GPRC5D with a CD58 Fusion Peptide 304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO0097 304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00304743675Attorney Docket No. E0701.70010WO00

[0167] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), and a third light chain polypeptide (L3). In some embodiments, the present disclosure contemplates a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprising a combination of H1, L1, H2, L2, and L3 from any one of the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecules listed in Table 17 at any of the disclosed sequence identities.

[0168] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain polypeptide (L3), and a CD58 polypeptide fused to the N-terminus of H1. In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain polypeptide (L3), and a CD58 polypeptide fused to the C-terminus of H1.

[0169] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain 304743675Attorney Docket No. E0701.70010WO00 polypeptide (L3), and a CD58 polypeptide fused to the N-terminus of H2. In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain polypeptide (L3), and a CD58 polypeptide fused to the C-terminus of H2.

[0170] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain polypeptide (L3), and a CD58 polypeptide fused to the N-terminus of L1. In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain polypeptide (L3), and a CD58 polypeptide fused to the C-terminus of L1.

[0171] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain polypeptide (L3), and a CD58 polypeptide fused to the N-terminus of L2. In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain polypeptide (L3), and a CD58 polypeptide fused to the C-terminus of L2.

[0172] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain polypeptide (L3), and a CD58 polypeptide fused to the N-terminus of L3. In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises: a 119 304743675Attorney Docket No. E0701.70010WO00 first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), a third light chain polypeptide (L3), and a CD58 polypeptide fused to the C-terminus of L3.

[0173] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; and (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2.

[0174] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2; and (iv) the 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the N-terminus of H1. In some embodiments, a 2:1 anti-GPRC5D / anti- CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the C-terminus of H1.

[0175] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second 120 304743675Attorney Docket No. E0701.70010WO00 antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2; and (iv) the 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the N-terminus of H2. In some embodiments, a 2:1 anti-GPRC5D / anti- CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the C-terminus of H2.

[0176] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2; and (iv) the 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the N-terminus of L1. In some embodiments, a 2:1 anti-GPRC5D / anti- CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 121 304743675Attorney Docket No. E0701.70010WO00 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further includes a CD58 polypeptide fused to the C-terminus of L1.

[0177] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3 (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2; and (iv) the 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the N-terminus of L2. In some embodiments, a 2:1 anti-GPRC5D / anti- CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the C-terminus of L2.

[0178] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2; and (iv) the 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the N-terminus of L3. In some embodiments, a 2:1 anti-GPRC5D / anti- CD3 multispecific antibody fusion molecule (e.g., any one of the multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a 122 304743675Attorney Docket No. E0701.70010WO00 Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on either H1 or H2 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further includes a CD58 polypeptide fused to the C-terminus of L3.

[0179] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain for binding CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on H2 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further includes a CD58 polypeptide fused to the C-terminus of H2.

[0180] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on H2 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the C-terminus of L3.

[0181] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding 123 304743675Attorney Docket No. E0701.70010WO00 domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on H2 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the C-terminus of H1.

[0182] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on H1 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the C-terminus of H2.

[0183] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on H1 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the C-terminus of L3.

[0184] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and an antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on H2 and a VL1 located on L2; and (iv) the 2:1 304743675Attorney Docket No. E0701.70010WO00 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the N-terminus of H2.

[0185] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule (e.g., a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecules described in Table 17) comprises a first antigen binding domain (e.g., a Fab) that binds to GPRC5D, a second antigen binding domain (e.g., a Fab) that binds to GPRC5D, and a third antigen binding domain that binds to CD3, in which (i) the second antigen binding domain comprises a VH2 located on H1 and a VL2 located on L1; (ii) the third antigen binding domain comprises a VH3 located on H2 and a VL3 located on L3; (iii) the first antigen binding domain comprises a VH1 located on H2 and a VL1 located on L2; and (iv) the 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule further comprises a CD58 polypeptide fused to the N-terminus of L3.

[0186] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_6. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 8, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 8, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0187] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_7. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 9, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 9, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0188] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_8. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 9, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 9, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0189] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_9. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 10, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 10, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0190] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_10. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 11, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 11, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 62.

[0191] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_11. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 11, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 11, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0192] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_12. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 12, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 10, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 12, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 10, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0193] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_13. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 12, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 11, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 12, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 11, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0194] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_14. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 12, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 11, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 12, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 11, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0195] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_15. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 13, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 6, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 13, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 6, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0196] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_16. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 13, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 7, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 13, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 7, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0197] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_17. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 13, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 7, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 13, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 7, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0198] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_18. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 13, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 14, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 13, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 14, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0199] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_19. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 13, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 15, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 13, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 15, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 62.

[0200] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_20. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 13, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 15, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 13, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 15, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0201] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_21. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 16, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 16, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0202] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_22. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 17, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 17, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0203] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_23. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 17, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 17, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0204] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_24. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 10, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 63. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 10, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 63.

[0205] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_25. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 11, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 64. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 11, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 64.

[0206] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_26. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 11, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 63. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 11, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 63.

[0207] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_33. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 18, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 18, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0208] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_34. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 19, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 19, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0209] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_35. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 19, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 19, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0210] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_36. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 20, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 20, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0211] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_37. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 21, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 21, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 62.

[0212] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_38. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 4, a L1 comprising the amino acid sequence of SEQ ID NO: 57, a H2 comprising the amino acid sequence of SEQ ID NO: 21, a L2 comprising the amino acid sequence of SEQ ID NO: 57, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 4, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 21, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 57, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0213] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is bsAb_2. In some embodiments, the a 2:1 anti-GPRC5D / anti- CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 22, a L1 comprising the amino acid sequence of SEQ ID NO: 65, a H2 comprising the amino acid sequence of SEQ ID NO: 23, a L2 comprising the amino acid sequence of SEQ ID NO: 65, and a L3 comprising the amino acid sequence of SEQ ID NO: 66. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 22, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 65, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 23, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 65, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 143 304743675Attorney Docket No. E0701.70010WO00 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 66.

[0214] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_39. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 22, a L1 comprising the amino acid sequence of SEQ ID NO: 65, a H2 comprising the amino acid sequence of SEQ ID NO: 24, a L2 comprising the amino acid sequence of SEQ ID NO: 65, and a L3 comprising the amino acid sequence of SEQ ID NO: 66. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 22, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 65, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 24, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 65, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 66.

[0215] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_44. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 27, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 27, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0216] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_45. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 28, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 28, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0217] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_46. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 28, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 28, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0218] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_47. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 29, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 29, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0219] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_48. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 30, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 30, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 62.

[0220] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_49. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 30, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 30, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0221] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_50. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 31, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 29, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 31, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 29, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0222] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_51. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 31, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 30, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 31, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 30, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0223] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_52. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 31, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 30, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 31, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 30, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0224] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_53. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 32, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 6, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 32, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 6, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0225] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_54. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 32, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 7, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 32, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 7, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0226] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_55. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 32, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 7, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 32, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 7, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0227] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_56. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 32, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 14, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 32, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 14, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0228] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_57. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 32, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 15, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 32, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 15, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 62.

[0229] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_58. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 32, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 15, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 32, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 15, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0230] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_59. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 33, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 33, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0231] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_60. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 34, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 34, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0232] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_61. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 34, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 34, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0233] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_62. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 29, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 63. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 29, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 63.

[0234] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_63. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 30, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 64. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 30, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 64.

[0235] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_64. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 30, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 63. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 30, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 63.

[0236] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_71. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 35, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 35, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0237] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_72. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 36, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 36, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0238] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_73. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 36, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 36, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0239] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_74. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 37, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 37, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0240] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_75. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 38, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 38, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 62.

[0241] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_76. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 25, a L1 comprising the amino acid sequence of SEQ ID NO: 67, a H2 comprising the amino acid sequence of SEQ ID NO: 38, a L2 comprising the amino acid sequence of SEQ ID NO: 67, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 25, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 38, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 67, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0242] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_81. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 42, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 43, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 42, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 43, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0243] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_82. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 42, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 44, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 42, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 44, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0244] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_83. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 42, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 44, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 42, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 44, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0245] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_84. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 42, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 45, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 42, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 45, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0246] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_85. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 42, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 46, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 42, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 46, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 62.

[0247] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_86. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 42, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 46, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 42, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 46, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 61.

[0248] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_87. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 47, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 45, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 47, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 45, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0249] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_88. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 47, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 46, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 47, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 46, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0250] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_89. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 47, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 46, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 47, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 46, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0251] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_90. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 48, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 6, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 48, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 6, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0252] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_91. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 48, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 7, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 48, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 7, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, 304743675Attorney Docket No. E0701.70010WO00 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 60.

[0253] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_92. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 48, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 7, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 48, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 7, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, and a L3 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 59.

[0254] In some embodiments, a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule described herein is EVOLVE_GPRC5D_93. In some embodiments, the a 2:1 anti- GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising the amino acid sequence of SEQ ID NO: 48, a L1 comprising the amino acid sequence of SEQ ID NO: 69, a H2 comprising the amino acid sequence of SEQ ID NO: 14, a L2 comprising the amino acid sequence of SEQ ID NO: 69, and a L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the a 2:1 anti-GPRC5D / anti-CD3 multispecific antibody fusion molecule comprises: a H1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at 304743675Attorney Docket No. E0701.70010WO00 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 48, a L1 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 69, a H2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 14, a L2 comprising an amino acid sequence at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at ...

Claims

Attorney Docket No. E0701.70010WO00 CLAIMS What is claimed is:

1. An antibody comprising a first antigen binding region that binds to GPRC5D, a second antigen binding region that binds to GPRC5D, and a third antigen binding region that binds to CD3, wherein the first antigen binding region that binds to GPRC5D comprises three heavy chain complementarity determining regions (VH1_CDR1, VH1_CDR2, VH1_CDR3) and three light chain complementarity determining regions (VL1_CDR1, VL1_CDR2, VL1_CDR3), wherein a) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 72; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 82; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 83; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 89; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 98; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 100; b) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 86; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; c) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 85; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; or d) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 77; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 79; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 88; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 93; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 94; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 103; 232 304743675Attorney Docket No. E0701.70010WO00 wherein the second antigen binding region that binds to GPRC5D comprises three heavy chain complementarity determining regions (VH2_CDR1, VH2_CDR2, VH2_CDR3) and three light chain complementarity determining regions (VL2_CDR1, VL2_CDR2, VL2_CDR3), wherein I) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 72; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 82; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 83; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 89; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 98; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 100; II) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 72; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 97; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 83; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 89; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 98; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 100; III) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 86; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; or IV) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 77; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 79; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 88; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 93; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 94; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 103; and wherein the third antigen binding region that binds to CD3 comprises three heavy chain complementarity determining regions (VH3_CDR1, VH3_CDR2, VH3_CDR3) and three light chain complementarity determining regions (VL3_CDR1, VL3_CDR2, VL3_CDR3), wherein 304743675Attorney Docket No. E0701.70010WO00 i) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 73; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; ii) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 74; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 95; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; iii) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 76; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 92; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 104; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 102; iv) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 74; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; or v) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 73; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 95; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO:

87. 304743675Attorney Docket No. E0701.70010WO00 2. The antibody of claim 1, wherein the first antigen binding region that binds to GPRC5D comprises a first variable heavy chain region (VH1) and a first variable light chain region (VL1), wherein: a) VH1 comprises the amino acid sequence of SEQ ID NO: 117; and VL1 comprises the amino acid sequence of SEQ ID NO: 131; b) VH1 comprises the amino acid sequence of SEQ ID NO: 120; and VL1 comprises the amino acid sequence of SEQ ID NO: 135; c) VH1 comprises the amino acid sequence of SEQ ID NO: 122; and VL1 comprises the amino acid sequence of SEQ ID NO: 137; or d) VH1 comprises the amino acid sequence of SEQ ID NO: 123; and VL1 comprises the amino acid sequence of SEQ ID NO: 138; wherein the second antigen binding region that binds to GPRC5D comprises a second variable heavy chain region (VH2) and a second variable light chain region (VL2), wherein: I) VH1 comprises the amino acid sequence of SEQ ID NO: 117; and VL1 comprises the amino acid sequence of SEQ ID NO: 131; II) VH1 comprises the amino acid sequence of SEQ ID NO: 120; and VL1 comprises the amino acid sequence of SEQ ID NO: 135; III) VH1 comprises the amino acid sequence of SEQ ID NO: 122; and VL1 comprises the amino acid sequence of SEQ ID NO: 137; or IV) VH1 comprises the amino acid sequence of SEQ ID NO: 123; and VL1 comprises the amino acid sequence of SEQ ID NO: 138; and wherein the third antigen binding region that binds to CD3 comprises a third variable heavy chain region (VH3) and a third variable light chain region (VL3), wherein: i) VH3 comprises the amino acid sequence of SEQ ID NO: 118; and VL3 comprises the amino acid sequence of SEQ ID NO: 132; ii) VH3 comprises the amino acid sequence of SEQ ID NO: 119; and VL3 comprises the amino acid sequence of SEQ ID NO: 133; iii) VH3 comprises the amino acid sequence of SEQ ID NO: 119; and VL3 comprises the amino acid sequence of SEQ ID NO: 132; or iv) VH3 comprises the amino acid sequence of SEQ ID NO: 121; and VL3 comprises the amino acid sequence of SEQ ID NO:

136. 304743675Attorney Docket No. E0701.70010WO00 3. The antibody of claim 2, wherein the antibody comprises a first heavy chain polypeptide (H1) and a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2), and a third light chain polypeptide (L3), wherein a) the first heavy chain polypeptide (H1) comprises the second variable heavy chain region (VH2); b) the second heavy chain polypeptide (H2) comprises the third variable heavy chain region (VH3); c) the first variable heavy chain region (VH1) is located on either the first heavy chain polypeptide (H1) or the second heavy chain polypeptide (H2), d) the first light chain polypeptide (L1) comprises the first variable light chain region (VL1), e) the second light chain polypeptide (L2) comprises the second variable light chain region (VL2), and f) the third light chain polypeptide (L3) comprises the third variable light chain region (VL3).

4. The antibody of claim 3, wherein a polypeptide is fused to the N-terminus or the C- terminus of the first heavy chain polypeptide (H1), the second heavy chain polypeptide (H2), or the third light chain polypeptide (L3).

5. The antibody of claim 4, wherein the polypeptide is fused via a linker peptide.

6. The antibody of claim 4 or 5, wherein the polypeptide comprises CD58 or a fragment thereof.

7. The antibody of claim 6, wherein the CD58 comprises the amino acid sequence of SEQ ID NO:

144.

8. The antibody of any one of claims 2-7, wherein i) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 117; the VH3 comprises the amino acid sequence of SEQ ID NO: 118; 304743675Attorney Docket No. E0701.70010WO00 the VL1 comprises the amino acid sequence of SEQ ID NO: 131; the VL2 comprises the amino acid sequence of SEQ ID NO: 131; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; ii) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 117; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; the VL2 comprises the amino acid sequence of SEQ ID NO: 131; and the VL3 comprises the amino acid sequence of SEQ ID NO: 133; iii) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 117; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; the VL2 comprises the amino acid sequence of SEQ ID NO: 131; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; iv) the VH1 comprises the amino acid sequence of SEQ ID NO: 120; the VH2 comprises the amino acid sequence of SEQ ID NO: 120; the VH3 comprises the amino acid sequence of SEQ ID NO: 121; the VL1 comprises the amino acid sequence of SEQ ID NO: 135; the VL2 comprises the amino acid sequence of SEQ ID NO: 135; and the VL3 comprises the amino acid sequence of SEQ ID NO: 136; v) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 122; the VH3 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; the VL2 comprises the amino acid sequence of SEQ ID NO: 137; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; vi) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 122; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; the VL2 comprises the amino acid sequence of SEQ ID NO: 137; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; 304743675Attorney Docket No. E0701.70010WO00 vii) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 123; the VH3 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; the VL2 comprises the amino acid sequence of SEQ ID NO: 138; and the VL3 comprises the amino acid sequence of SEQ ID NO: 132; viii) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 123; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; the VL2 comprises the amino acid sequence of SEQ ID NO: 138; and the VL3 comprises the amino acid sequence of SEQ ID NO: 133; or ix) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 123; the VH3 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; the VL2 comprises the amino acid sequence of SEQ ID NO: 138; and the VL3 comprises the amino acid sequence of SEQ ID NO:

132.

9. The antibody of claim 8, wherein i) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 8; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; ii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 9; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; iii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 9; the L1 comprises the amino acid sequence of SEQ ID NO: 57; 304743675Attorney Docket No. E0701.70010WO00 the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; iv) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 10; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; v) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; vi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; vii) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 10; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; viii) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; ix) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; x) the H1 comprises the amino acid sequence of SEQ ID NO: 13; 304743675Attorney Docket No. E0701.70010WO00 the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xi) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xii) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xiii) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xiv) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; xv) the H1 comprises the amino acid sequence of SEQ ID NO: 13; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xvi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 16; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and 304743675Attorney Docket No. E0701.70010WO00 the L3 comprises the amino acid sequence of SEQ ID NO: 59; xvii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 17; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xviii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 17; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xix) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 10; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; xx) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 64; xxi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 11; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; xxii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 18; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 19; 304743675Attorney Docket No. E0701.70010WO00 the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 19; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxv) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 20; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xxvi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 21; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; xxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 21; the L1 comprises the amino acid sequence of SEQ ID NO: 57; the L2 comprises the amino acid sequence of SEQ ID NO: 57; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 22; the H2 comprises the amino acid sequence of SEQ ID NO: 23; the L1 comprises the amino acid sequence of SEQ ID NO: 65; the L2 comprises the amino acid sequence of SEQ ID NO: 65; and the L3 comprises the amino acid sequence of SEQ ID NO: 66; xxix) the H1 comprises the amino acid sequence of SEQ ID NO: 22; the H2 comprises the amino acid sequence of SEQ ID NO: 24; the L1 comprises the amino acid sequence of SEQ ID NO: 65; the L2 comprises the amino acid sequence of SEQ ID NO: 65; and the L3 comprises the amino acid sequence of SEQ ID NO: 66; 304743675Attorney Docket No. E0701.70010WO00 xxx) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 27; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxxi) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 28; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xxxii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 28; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 29; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xxxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; xxxv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xxxvi) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 29; the L1 comprises the amino acid sequence of SEQ ID NO: 67; 304743675Attorney Docket No. E0701.70010WO00 the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xxxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xxxix) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xl) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xli) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xlii) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xliii) the H1 comprises the amino acid sequence of SEQ ID NO: 32; 304743675Attorney Docket No. E0701.70010WO00 the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; xliv) the H1 comprises the amino acid sequence of SEQ ID NO: 32; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; xlv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 33; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xlvi) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 34; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; xlvii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 34; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; xlviii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 29; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; xlix) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and 304743675Attorney Docket No. E0701.70010WO00 the L3 comprises the amino acid sequence of SEQ ID NO: 64; l) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 30; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; li) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 35; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 36; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; liii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 36; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; liv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 37; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 38; the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; lvi) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 38; 304743675Attorney Docket No. E0701.70010WO00 the L1 comprises the amino acid sequence of SEQ ID NO: 67; the L2 comprises the amino acid sequence of SEQ ID NO: 67; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lvii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 43; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lviii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 44; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lix) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 44; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lx) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 45; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lxi) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; lxii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; 304743675Attorney Docket No. E0701.70010WO00 lxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 45; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lxv) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxvi) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lxix) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 69; 304743675Attorney Docket No. E0701.70010WO00 the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lxx) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 62; lxxi) the H1 comprises the amino acid sequence of SEQ ID NO: 48; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lxxii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 147; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 148; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lxxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 148; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxxv) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 45; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; lxxvi) the H1 comprises the amino acid sequence of SEQ ID NO: 42; 304743675Attorney Docket No. E0701.70010WO00 the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 64; lxxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 46; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 63; lxxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 51; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxxix) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 149; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 60; lxxx) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 149; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 59; lxxxi) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 150; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO: 61; lxxxii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 151; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and 304743675Attorney Docket No. E0701.70010WO00 the L3 comprises the amino acid sequence of SEQ ID NO: 62; or lxxxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 151; the L1 comprises the amino acid sequence of SEQ ID NO: 69; the L2 comprises the amino acid sequence of SEQ ID NO: 69; and the L3 comprises the amino acid sequence of SEQ ID NO:

61.

9. A polynucleotide comprising a nucleic acid sequence encoding the antibody of any one of claims 1-8.

10. A vector comprising the polynucleotide of claim 9.

11. A pharmaceutical composition comprising the antibody of any one of claims 1-8, the polynucleotide of claim 9, or the vector of claim 10, and a pharmaceutically acceptable carrier.

12. A bispecific antibody comprising a first antigen binding region that binds to GPRC5D, and a second antigen binding region that binds to CD3, wherein the first antigen binding region that binds to GPRC5D comprises three heavy chain complementarity determining regions (VH1_CDR1, VH1_CDR2, VH1_CDR3) and three light chain complementarity determining regions (VL1_CDR1, VL1_CDR2, VL1_CDR3), wherein a) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 72; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 82; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 83; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 89; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 98; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 100; b) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 86; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and 251 304743675Attorney Docket No. E0701.70010WO00 VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; c) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 75; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 80; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 85; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 91; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 96; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 101; or d) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 77; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 79; VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 88; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 93; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 94; and VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 103; wherein the second antigen binding region that binds to CD3 comprises three heavy chain complementarity determining regions (VH2_CDR1, VH2_CDR2, VH2_CDR3) and three light chain complementarity determining regions (VL2_CDR1, VL2_CDR2, VL2_CDR3), wherein i) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 74; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 104; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; ii) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 73; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; or iii) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 74; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 78; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 84; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 90; 252 304743675Attorney Docket No. E0701.70010WO00 VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 95; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 87; or iv) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 92; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 104; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 102; VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 76; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 81; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO:

87.

13. The bispecific antibody of claim 12, wherein the first antigen binding region that binds to GPRC5D comprises a first variable heavy chain region (VH1) and a first variable light chain region (VL1), wherein: a) VH1 comprises the amino acid sequence of SEQ ID NO: 126; and VL1 comprises the amino acid sequence of SEQ ID NO: 143; b) VH1 comprises the amino acid sequence of SEQ ID NO: 117; and VL1 comprises the amino acid sequence of SEQ ID NO: 131; c) VH1 comprises the amino acid sequence of SEQ ID NO: 122; and VL1 comprises the amino acid sequence of SEQ ID NO: 137; or d) VH1 comprises the amino acid sequence of SEQ ID NO: 123; and VL1 comprises the amino acid sequence of SEQ ID NO: 138; wherein the second antigen binding region that binds to CD3 comprises a second variable heavy chain region (VH2) and a second variable light chain region (VL2), wherein: i) VH2 comprises the amino acid sequence of SEQ ID NO: 125; and VL2 comprises the amino acid sequence of SEQ ID NO: 142; ii) VH2 comprises the amino acid sequence of SEQ ID NO: 127; and VL2 comprises the amino acid sequence of SEQ ID NO: 142; iii) VH2 comprises the amino acid sequence of SEQ ID NO: 118; and VL2 comprises the amino acid sequence of SEQ ID NO: 132; iv) VH2 comprises the amino acid sequence of SEQ ID NO: 119; and VL2 comprises the amino acid sequence of SEQ ID NO: 133; v) VH2 comprises the amino acid sequence of SEQ ID NO: 119; and VL2 comprises the amino acid sequence of SEQ ID NO: 132; or vi) VH2 comprises the amino acid sequence of SEQ ID NO: 128; and VL2 comprises the amino acid sequence of SEQ ID NO:

141. 304743675Attorney Docket No. E0701.70010WO00 14. The bispecific antibody of claim 13, wherein the bispecific antibody comprises a first heavy chain polypeptide (H1) and a second heavy chain polypeptide (H2), a first light chain polypeptide (L1), a second light chain polypeptide (L2) wherein, a) the first heavy chain polypeptide (H1) comprises the first variable heavy chain region (VH1); b) the second heavy chain polypeptide (H2) comprises the second variable heavy chain region (VH2); c) the first light chain polypeptide (L1) comprises the first variable light chain region (VL1); and d) the second light chain polypeptide (L2) comprises the second variable light chain region (VL2).

15. The bispecific antibody of claim 14, wherein a polypeptide is fused to the N- terminus or the C-terminus of the first heavy chain polypeptide (H1), the second heavy chain polypeptide (H2), or the third light chain polypeptide (L3).

16. The bispecific antibody of claim 15, wherein the polypeptide is fused via a linker peptide.

17. The bispecific antibody of claim 15 or 16, wherein the polypeptide comprises CD58 or a fragment thereof.

18. The bispecific antibody of claim 17, wherein the CD58 comprises the amino acid sequence of SEQ ID NO:

144.

19. The bispecific antibody of any one of claims 13-18, wherein i) the VH1 comprises the amino acid sequence of SEQ ID NO: 126; the VH2 comprises the amino acid sequence of SEQ ID NO: 125; the VL1 comprises the amino acid sequence of SEQ ID NO: 143; and the VL2 comprises the amino acid sequence of SEQ ID NO: 142; ii) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 127; 304743675Attorney Docket No. E0701.70010WO00 the VL1 comprises the amino acid sequence of SEQ ID NO: 131; and the VL2 comprises the amino acid sequence of SEQ ID NO: 142; iii) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132; iv) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; and the VL2 comprises the amino acid sequence of SEQ ID NO: 133; v) the VH1 comprises the amino acid sequence of SEQ ID NO: 117; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 131; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132; vi) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 128; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; and the VL2 comprises the amino acid sequence of SEQ ID NO: 141; vii) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132; viii) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; and the VL2 comprises the amino acid sequence of SEQ ID NO: 133; ix) the VH1 comprises the amino acid sequence of SEQ ID NO: 122; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 137; and the VL2 comprises the amino acid sequence of SEQ ID NO: 132; x) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 118; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; and 304743675Attorney Docket No. E0701.70010WO00 the VL2 comprises the amino acid sequence of SEQ ID NO: 132; xi) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; and the VL2 comprises the amino acid sequence of SEQ ID NO: 133; or xii) the VH1 comprises the amino acid sequence of SEQ ID NO: 123; the VH2 comprises the amino acid sequence of SEQ ID NO: 119; the VL1 comprises the amino acid sequence of SEQ ID NO: 138; and the VL2 comprises the amino acid sequence of SEQ ID NO:

132.

20. The bispecific antibody of claim 19, wherein i) the H1 comprises the amino acid sequence of SEQ ID NO: 1; the H2 comprises the amino acid sequence of SEQ ID NO: 2; the L1 comprises the amino acid sequence of SEQ ID NO: 55; and the L2 comprises the amino acid sequence of SEQ ID NO: 56; ii) the H1 comprises the amino acid sequence of SEQ ID NO: 1; the H2 comprises the amino acid sequence of SEQ ID NO: 3; the L1 comprises the amino acid sequence of SEQ ID NO: 55; and the L2 comprises the amino acid sequence of SEQ ID NO: 56; iii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 5; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 58; iv) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; v) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; vi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 7; 304743675Attorney Docket No. E0701.70010WO00 the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; vii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; viii) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 62; xi) the H1 comprises the amino acid sequence of SEQ ID NO: 4; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; x) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xi) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; xii) the H1 comprises the amino acid sequence of SEQ ID NO: 12; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 57; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xiii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 26; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 68; xiv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 65; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and 304743675Attorney Docket No. E0701.70010WO00 the L2 comprises the amino acid sequence of SEQ ID NO: 59; xv) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; xvi) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xvii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; xviii) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 62; xix) the H1 comprises the amino acid sequence of SEQ ID NO: 25; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; xx) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xxi) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; xxii) the H1 comprises the amino acid sequence of SEQ ID NO: 31; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 67; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; 304743675Attorney Docket No. E0701.70010WO00 xxiii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 6; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xxiv) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; xxv) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 7; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xxvi) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; xxvii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 62; xxviii) the H1 comprises the amino acid sequence of SEQ ID NO: 42; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 61; xxix) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 14; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 59; xxx) the H1 comprises the amino acid sequence of SEQ ID NO: 47; the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO: 60; or xxxi) the H1 comprises the amino acid sequence of SEQ ID NO: 47; 304743675Attorney Docket No. E0701.70010WO00 the H2 comprises the amino acid sequence of SEQ ID NO: 15; the L1 comprises the amino acid sequence of SEQ ID NO: 69; and the L2 comprises the amino acid sequence of SEQ ID NO:

59.

21. A polynucleotide comprising a nucleic acid sequence encoding the bispecific antibody of any one of claims 12-20.

22. A vector comprising the polynucleotide of claim 21.

23. A pharmaceutical composition comprising the bispecific antibody of any one of claims 12-20, the polynucleotide of claim 21, or the vector of claim 22, and a pharmaceutically acceptable carrier.

24. A trispecific antibody comprising a first antigen binding region that binds to GPRC5D, a second antigen binding region that binds to BCMA, and a third antigen binding region that binds to CD3, wherein the first antigen binding region that binds to GPRC5D comprises three heavy chain complementarity determining regions (VH1_CDR1, VH1_CDR2, VH1_CDR3) and three light chain complementarity determining regions (VL1_CDR1, VL1_CDR2, VL1_CDR3), wherein a) VH1_CDR1 comprises the amino acid sequence of SEQ ID NO: 77; VH1_CDR2 comprises the amino acid sequence of SEQ ID NO: 79; and VH1_CDR3 comprises the amino acid sequence of SEQ ID NO: 88; VL1_CDR1 comprises the amino acid sequence of SEQ ID NO: 93; VL1_CDR2 comprises the amino acid sequence of SEQ ID NO: 94; VL1_CDR3 comprises the amino acid sequence of SEQ ID NO: 103; wherein the second antigen binding region that binds to BCMA comprises three heavy chain complementarity determining regions (VH2_CDR1, VH2_CDR2, VH2_CDR3) and three light chain complementarity determining regions (VL2_CDR1, VL2_CDR2, VL2_CDR3), wherein I) VH2_CDR1 comprises the amino acid sequence of SEQ ID NO: 111; VH2_CDR2 comprises the amino acid sequence of SEQ ID NO: 112; VH2_CDR3 comprises the amino acid sequence of SEQ ID NO: 113; 260 304743675Attorney Docket No. E0701.70010WO00 VL2_CDR1 comprises the amino acid sequence of SEQ ID NO: 105; VL2_CDR2 comprises the amino acid sequence of SEQ ID NO: 106; and VL2_CDR3 comprises the amino acid sequence of SEQ ID NO: 107; and wherein the third antigen binding region that binds to CD3 comprises three heavy chain complementarity determining regions (VH3_CDR1, VH3_CDR2, VH3_CDR3) and three light chain complementarity determining regions (VL3_CDR1, VH3_CDR2, VH3_CDR3), wherein i) VH3_CDR1 comprises the amino acid sequence of SEQ ID NO: 108; VH3_CDR2 comprises the amino acid sequence of SEQ ID NO: 109; VH3_CDR3 comprises the amino acid sequence of SEQ ID NO: 110; VL3_CDR1 comprises the amino acid sequence of SEQ ID NO: 114; VL3_CDR2 comprises the amino acid sequence of SEQ ID NO: 115; and VL3_CDR3 comprises the amino acid sequence of SEQ ID NO:

116.

25. The trispecific antibody of claim 24, wherein the first antigen binding region that binds to GPRC5D comprises a first variable heavy chain region (VH1) and a first variable light chain region (VL1), wherein: a) VH1 comprises the amino acid sequence of SEQ ID NO: 139; and VL1 comprises the amino acid sequence of SEQ ID NO: 129; wherein the second antigen binding region that binds to BCMA comprises a second variable heavy chain region (VH2) and a second variable light chain region (VL2), wherein: I) VH1 comprises the amino acid sequence of SEQ ID NO: 145; and VL1 comprises the amino acid sequence of SEQ ID NO: 146; and wherein the third antigen binding region that binds to CD3 comprises a third variable heavy chain region (VH3) and a third variable light chain region (VL3), wherein: i) VH3 comprises the amino acid sequence of SEQ ID NO: 130; and VL3 comprises the amino acid sequence of SEQ ID NO:

140.

26. The trispecific antibody of claim 25, wherein the trispecific antibody comprises a first heavy chain polypeptide (H1), a second heavy chain polypeptide (H2), a third heavy chain polypeptide (H3), a first light chain polypeptide (L1), a second light chain polypeptide (L2), and a third light chain polypeptide (L3) wherein, 304743675Attorney Docket No. E0701.70010WO00 a) the first heavy chain polypeptide (H1) comprises the first variable heavy chain region (VH1); b) the second heavy chain polypeptide (H2) comprises the second variable heavy chain region (VH2); c) the third heavy chain polypeptide (H3) comprises the third variable heavy chain region (VH3); d) the first light chain polypeptide (L1) comprises the first variable light chain region (VL1); e) the second light chain polypeptide (L2) comprises the second variable light chain region (VL2); and f) the third light chain polypeptide (L3) comprises the third variable light chain region.

27. The trispecific antibody of claim 26, wherein a polypeptide is fused to the N- terminus or the C-terminus of the second heavy chain polypeptide (H2), the third heavy chain polypeptide (H3), the first light chain polypeptide (L1), the second light chain polypeptide (L2), or the third light chain polypeptide (L3).

28. The trispecific antibody of claim 27, wherein the polypeptide is fused via a linker peptide.

29. The trispecific antibody of claim 27 or 28, wherein the polypeptide comprises CD58 or a fragment thereof.

30. The trispecific antibody of claim 29, wherein the CD58 comprises the amino acid sequence of SEQ ID NO:

144.

31. The trispecific antibody of any one of claims 25-30, wherein i) the VH1 comprises the amino acid sequence of SEQ ID NO: 139; the VH2 comprises the amino acid sequence of SEQ ID NO: 145; the VH3 comprises the amino acid sequence of SEQ ID NO: 130; the VL1 comprises the amino acid sequence of SEQ ID NO: 129; the VL2 comprises the amino acid sequence of SEQ ID NO: 146; and 304743675Attorney Docket No. E0701.70010WO00 the VL3 comprises the amino acid sequence of SEQ ID NO:

140. 304743675

Images